Hepatitis C Community
How to get Abstracts From Liver Meeting 2008 (AASLD)
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

How to get Abstracts From Liver Meeting 2008 (AASLD)

Here's how to access the abstracts at Liver Meeting 2008.  A list of all abstracts under the heading of "viral hepatitis" will follow.  Not sure if late breaking abstracts are included.

(1) Go to: http://www.aasld.org/Pages/Default.aspx
(2) Register (We're all Hep C researchers, aren't we)
(3) Sign in
(4) click on "Liver meeting 2008"
(5) click on "Abstract and Presenters" (left bar)
(6) click on "View Itinerary Planner"
(7) click on "Search" (left bar)
(8) Fill out Search forum as appropriate. For the global search below, I simply went to "categories" and chose "viral hepatitis" from the drop down menu. I left the other fields blank. For more specific searches -- such as by sub topics or author - fill out appropriate fields.
Related Discussions
53 Comments Post a Comment
Blank
Avatar_m_tn

1790. Accelerated Fibrosis Progression in African-American (AA) Liver Transplant (LT) Recipients with Hepatitis C Virus (HCV).  K. R. Krishnan; R. Kim; M. G. Peters; S. Feng; J. P. Roberts; N. Terrault View Pres.


1791. Diagnostic accuracy of Transient Elastography: a comparison between chronic hepatitis B and C correlated with optimal-length liver biopsies..  C. Verveer; B. E. Hansen; P. E. Zondervan; H. L. Janssen; R. J. de Knegt View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1780. Characterization of hepatitis C virus carriers with persistently normal ALT levels by human leukocyte antigen alleles and proteomics analysis.  F. Sasaki; H. Uto; Y. Sato; K. Kumagai; M. Oketani; A. Ido; K. Kusumoto; K. Hayashi; S. Stuver; T. Okanoue; H. Tsubouchi View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1781. The HCV Serum Proteome: A Search for Fibrosis Protein Markers.  K. Cheung; K. Tilleman; D. Deforce; I. Colle; H. Van Vlierberghe View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1767. Ferroportin c.1-310 CGG(7_9) as potential predictor for the treatment response in hepatitis C.  T. Ellermeyer; J. Büttner; S. Kaiser; H. G. Hass; E. Gentz; T. Fiedler; B. Bochow; R. Weltrich; H. Lochs; H. Schmidt View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1788. Effective use of FibroTest attributes to generate decision trees in hepatitis C.  D. Lau-Corona; L. A. Pineda; H. H. Avilés; G. Gutierrez-Reyes; B. E. Farfan-Labonne; R. Nuñez-Nateras; A. Bonder; R. Martinez-Garcia; C. Gutierrez Ruiz; C. Corona-Lau; M. A. Olivera-Martinez; E. Wolpert; G. Robles-Diaz; D. Kershenobich View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1795. COMPARISON OF LIVER STIFFNESS , FIBROTEST AND LIVER BIOPSY FOR THE ASSESSMENT OF LIVER FIBROSIS IN RENAL TRANSPLANT PATIENT WITH CHRONIC VIRAL HEPATITIS .  L. Alric; N. Kamar; M. Danjou; S. THebault; L. Rostaing View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1789. Blood tests of liver fibrosis in patients co-infected with HIV and HCV.  P. Cales; P. Halfon; D. Batisse; F. Carrat; P. Perré; G. Penaranda; D. Guyader; L. d'Alteroche; C. Michelet; P. Veillon; L. Weiss; P. Cacoub View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected
Blank
Avatar_m_tn

1793. Between-laboratory variations for Fibrotest-Actitest measurement in patients with hepatitis C in ANRS HC EP 23 Fibrostar study..  J. Guéchot; E. Lasnier; M. Vaubourdolle; A. Paris; J. Zarski View Pres.

1779. Interim Analysis of the Natural History of Chronic Hepatitis C Genotype 1 and 6.  W. Seto; C. Lai; J. Fung; J. L. Young; J. Yuen; D. Wong; M. Yuen View Pres.

1792. Acoustic Radiation Force Elastography versus Transient Elastography for non-invasive assessment of liver fibrosis in viral hepatitis: a new Alternative? .  M. Friedrich-Rust; K. Wunder; F. Sotoudeh; S. Kriener; S. Martens; T. Poynard; E. Herrmann; J. Bojunga; S. Zeuzem; C. Sarrazin View Pres.

1766. PREVALENCE AND CAUSES OF DISCORDANCE BETWEEN FIBROSCAN AND FIBROTEST FOR FIRST-LINE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS C (CHC): A PROSPECTIVE ANALYSIS OVER 4 YEARS IN 3148 PATIENTS .  L. Castera; M. Haaser; B. Le Bail; J. Foucher; P. Bernard; W. Merrouche; V. de Ledinghen ; P. Couzigou View Pres.

1796. Combination of 13C-methacetin breath test by online molecular correlation spectroscopy and transient elastography improves diagnostic performance of non-invasive fibrosis assessment in chronic hepatitis C.  O. Goetze; A. Grau; A. Geier ; T. Gerlach; M. Fried; B. Mullhaupt View Pres.

1783. A simple diagnostic algorithm to evaluate liver fibrosis in patients with chronic hepatitis C .  S. M. Martinez; M. Bruguera; J. M. Barrera; X. Forns; J. M. Sánchez-Tapias View Pres.

1768. Acute /recent HCV infection. Clinical Laboratory variants. Host andViral characteristics..  T. Tsertsvadze; L. Sharvadze; M. Karchava; A. Abutidze; E. Dolmazashvili View Pres.


1784. Follow-up study of ALT levels in patients with Chronic Hepatitis C and baseline normal ALT..  B. Ruiz-Antorán; J. Calleja-Panero; O. Nuñez; D. Suárez; M. Barenys-De Lacha; J. Ortiz-Seuma; I. Latorre; B. Peñas; J. de la Revilla View Pres.


1782. Noninvasive Monitoring of Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C.  C. Liu; C. Liang; C. Liu; S. Hsu; J. Lin; S. Chen; H. Tsai; P. Hung; M. Lai; P. Chen; J. Chen; J. Kao; D. Chen View Pres.


1785. Predicting Clinical Outcome Using Standard Laboratory Tests: Analysis of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Cohort..  M. G. Ghany; A. F. Lok; J. E. Everhart; G. T. Everson; W. M. Lee; T. M. Curto; E. C. Wright; A. M. Stoddard View Pres.

1769. Correlation of transient elastography (FibroScan) and hepatic artery doppler sonography in patients 30 years after single source hepatitis C genotype 1B outbreak in Germany.  I. Schiefke; M. Wiese; J. Wiegand View Pres.
Blank
Avatar_m_tn

1765. A SEQUENTIAL PREDICTIVE ALGORITHM COMBINING APRI AND TRANSIENT ELASTOGRAPHY (TE) FOR DIAGNOSING LIVER FIBROSIS IN CHRONIC HEPATITIS C..  M. Fraquelli; C. Rigamonti; G. Casazza; A. Colli; M. Rumi; D. Conte; M. Donato; G. Ronchi; M. Colombo View Pres.

1775. HBV superinfection in HCV chronic carriers is associated with severe acute hepatitis and clearance of HCV chronic replication.  N. Coppola; M. Pisaturo; A. Masiello; G. Tonziello; C. Sagnelli; V. Messina; P. Filippini; E. Sagnelli View Pres.


1764. Re-evaluation of the genetic cirrhosis risk score in patients with chronic hepatitis C virus infection.  F. Grünhage; T. Mueller; R. Günther; C. Hellerbrand; U. Spengler; C. P. Strassburg; B. Schlosser; V. Weich; H. Wasmuth; F. Lammert; T. Berg View Pres.

1776. Error Factors for Transient Elastography in Chronic Hepatitis C.  V. Calvaruso; C. Cammà; V. Di Marco; S. Maimone; F. Bronte; M. Enea; M. Pleguezuelo; E. Xirouchakis; M. Misseri; P. Manousou; G. M. Dusheiko; A. K. Burroughs; A. Craxì View Pres.


1774. Spontaneous viral clearance in HCV seroconverters .  C. van den Berg; J. Schinkel; T. J. van de Laar; R. Molenkamp; D. van Baarle; R. Coutinho; M. Prins View Pres.


1770. The Impact of Hepatic Steatosis on the Natural History of Chronic Hepatitis C Infection (CHC) Infection.  T. J. Cross; A. Quaglia; S. Hughes; D. Joshi; P. M. Harrison View Pres.

1771. Evaluation of Transient Elastography and King’s Score for the Diagnosis of Fibrosis in Patients with Chronic Hepatitis C Infection.  T. J. Cross; V. Calvaruso; S. Maimone; I. Carey; A. Quaglia; F. Grillo; G. M. Dusheiko; A. K. Burroughs; P. M. Harrison View Pres.

1786. Sequence Analysis of the Hepatitis C Virus in Patients who Relapse after Sustained Virologic Response: Relapse or Reinfection?.  K. Hara; T. Heller; P. Nagabhyru; T. Liang; J. H. Hoofnagle View Pres.


1777. Hepatic steatosis decreases with advancing hepatic fibrosis: findings from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial (HALT-C).  A. F. Lok; J. E. Everhart; R. T. Chung; H. Kim; G. T. Everson; J. C. Hoefs; J. K. Greenson View Pres.

1794. Mortality and end-stage liver disease related to hepatitis C in injecting drug users..  K. B. Kielland; O. Dalgard View Pres.


1772. HCV in Liver Cancer Patients Has Characteristic Mutations in the Core Gene.  S. Fishman; S. Factor; C. Balestrieri; S. M. Desai; A. M. Di Bisceglie; G. Benson; A. D.

1778. Coffee Intake Is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C: Findings from the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial .  N. D. Freedman; J. E. Everhart; K. Lindsay; M. G. Ghany; T. M. Curto; C. C. Abnet; R. Sinha View Pres.


1787. Neurocognitive Changes in CHC patients: the Effect of Interferon Therapy.  F. Barakat; D. L. Oliver; O. Vigil; M. Cherner; S. Woods; R. K. Heaton; I. Grant; S. Letendre; W. Perry; T. Hassanein View Pres.



1773. FibroTest diagnostic value according to ethnic origin and chronic viral hepatitis C (CHC) and B (CHB) etiology..  M. Munteanu ; Y. Ngo; V. Thibault; R. Morra; D. Messous; Y. Benhamou; F. Imbert-Bismut; T. Poynard View Pres.

Blank
Avatar_m_tn



839. Identifying transmission pairs in hepatitis B source and contact tracing: agreement of epidemiological and phylogenetic analysis in the multi-ethnic community of Rotterdam (2002-2005).  I. K. Veldhuijzen; T. H. Mes; M. C. Mostert; H. G. Niesters; S. D. Pas; J. J. Voermans; R. A. De Man; H. M. Götz; G. J. van Doornum; J. Richardus View Pres.


858. High HBV DNA load, HBeAg positivity and considerable hepatic necro inflammation in patients with incidentally detected, asymptomatic chronic HBV-infected individuals from Bangladesh.  A. Mamun; R. Salimur; S. Akbar; K. Mobin; K. Md. Fazal; K. Md. View Pres.


859. Lack of correlation between viral load and extent of liver damages in patients with chronic HBV infection at Bangladesh.  A. Mamun; R. Salimur; S. Akbar; K. Mobin; K. Md. Fazal; K. Md. View Pres.


831. High Prevalence of Hepatic Steatosis and its Impact on Fibrosis in Chronic Hepatitis B.  W. Bleibel; G. Hussain; M. Lai; C. Hayne; N. H. Afdhal; D. Lau View Pres.

815. Age-specific prognosis following HBeAg seroconversion in chronic hepatitis B.  Y. Chen; C. Chu; C. Yeh; Y. Liaw View Pres.


821. Surface Antigen Seroconversion after Allogenic Hematopoietic Stem Cell Transplantation in Patient with Chronic Hepatitis B Virus Infection.  S. Woo; C. Kim; S. Nam; J. Choi; S. Cho; J. Yang; J. Han; Y. Lee View Pres.


820. Fusion HBx from HBV integrant in human hepatoma cell line is implicated in the development and progression of hepatocellular carcinoma.  R. Muroyama; N. Kato; M. Otsuka; J. Chang; M. Omata View Pres.


819. Mechanism of hepatitis B virus persistence following an acute infection – a study using duck hepatitis B virus of the roles of virus replication and cell turnover..  G. Reaiche; M. Le Mire; W. Mason; A. R. Jilbert View Pres.


832. RIG-I signaling Expression in Monocyte-derived Dendritic Cells in Patients with Hepatitis B virus infection.  G. Zhao; Q. Xie; H. Wang; L. Lin; H. Zhou; N. Jia; Y. Yang; C. Shi; B. Gong; X. Xiang; Q. Huang; Q. Guo; H. Yu View Pres.

818. Reactive oxygen species induce liver fibrosis in uPA/SCID mice with human hepatocytes infected with specific hepatitis B virus genotypes.  M. Sugiyama; Y. Tanaka; I. Maruyama; T. Shimada; S. Takahashi; T. Shirai; K. Hino; I. Sakaida; M. Mizokami View Pres.


834. T-1993C Polymorphism in The Promoter of TBX21 Gene Is Associated With Susceptibility to Persistent Hepatitis B Virus Infection.  S. Chen; W. Zhao; G. Deng View Pres.


844. Single nucleotide polymorphisms and functional analysis of Class II transactivator (CIITA) coding region in chronic HBV infection.  X. Zhang View Pres.


862. Hepatitis B Virus Basal Core Promoter Mutation and DNA Load Correlate with Expression of Hepatitis B Core Antigen.  C. Liu; P. Chen; Y. Jeng; J. Kao; D. Chen View Pres.


851. Influences of hepatitis B virus genotype and precore mutations on reactivation of occult hepatitis B in patients with hematological malignancy.  F. Sugauchi; Y. Tanaka; T. Sakamoto; A. Kusakabe; K. Mtsuura; M. Sugiyama; S. Nojiri; J. Takashi; M. Mizokami View Pres.

Blank
Avatar_m_tn

867. Accumulation of Hepatitis B Virus DNA in hepatocellular carcinoma of patients with sustained virological response for hepatitis C virus .  A. Tamori; T. Hayashi; M. Shinzaki; S. Kobayshi; S. Iwai; H. Morikawa; M. Enomoto; H. Sakaguchi; S. Shiomi; S. Kubo; N. Kawada View Pres.


826. CD4+LAP+ regulatory T cells mediate the enhancement of the anti-HBV immune response: A novel method for an adjuvant-dependent augmentation of anti-viral immunity.  M. Mizrahi; G. Lalazar; A. Ben Ya'akov; T. Adar; L. Zolotarov; Y. Ilan View Pres.



868. Increasing frequency of acute hepatitis B with imported strain genotype A in Japan.  Y. Tamada; K. Yano; A. Komori; S. Abiru; K. Migita; M. Nakamura; H. Fujioka; H. Yatsuhashi; H. Ishibashi View Pres.



833. Hepatitis B virus-replication could induce sHSP60 and enhance regulatory T cell activity via toll like receptor 2..  Y. Kondo; Y. Ueno; S. Kon; J. Inoue; M. Ninomiya; E. Kakazu; M. Shiina; K. Tamai; Y. Wakui; K. Kobayashi; K. Fukushima; T. Kogure; H. Niitsuma; Y. Tanaka; M. Mizokami; T. Shimosegawa View Pres.



822. Cytopathic effect of hepatitis B virus obtained from fulminant hepatitis patients.  J. Inoue; Y. Ueno; Y. Wakui; K. Fukushima; T. Kogure; Y. Kondo; E. Kakazu; H. Niitsuma; T. Shimosegawa View Pres.



863. Drifting of HBV specific CTL epitope HBcAg18-27V to HBcAg18-27I in most HBV genotype B and C virus strains in China.  S. Ma; M. Liang; X. Hu; Y. Yu; J. Chen; L. Yang; C. Li; X. Xu; Z. Wang; J. Hou View Pres.



827. Perinatal transmission of hepatitis B virus: viral load and HBeAg status are significant risk factors.  E. Wiseman; M. A. Fraser; S. Holden; A. L. Glass; B. Kidson; L. G. Heron; M. Maley; A. Ayres; S. Locarnini; M. Levy View Pres.


838. Histological Findings Of HBeAg-negative Chronic HBV -Infected Patients With Persistently Normal Serum Alanine Aminotransferase Levels.  Q. Xie; Y. Yang; H. Zhou; H. Wang; H. Gui; L. Lin; W. Cai; W. Zhu; X. Xiang; B. Gong; Q. Guo; H. Yu View Pres.


861. Hepatitis B Viral Factors Influencing the Histological Changes Of HBeAg-negative Chronic HBV Infected Patients With Persistently Normal Serum Alanine Aminotransferase Levels.  Y. Yang; Q. Xie; H. Zhou; H. Wang; H. Gui; W. Cai; L. Lin; G. Zhao; C. Shi; H. Yu; Q. Guo View Pres.


864. Large deletion mutants of hepatitis B virus with amino acid substitutions in the core region emerges and dominates around the onset of active hepatitis in persistent HBV carriers.  N. Yamada; H. Yotsuyanagi; H. Miyoshi; T. Tsutsumi; H. Fujie; Y. Shintani; K. Moriya; C. Okuse; M. Suzuki; F. Itoh; K. Yasuda; S. Iino; K. Koike View Pres.


828. Cellular immune response to recombinant surface and core HBV antigens is not impaired in blood donors with occult hepatitis B infection.  M. Bes; S. Sauleda; N. Casamitjana; A. Esplugas; J. I. Esteban; M. Pirón; L. Puig; J. Guardia; V. Vargas View Pres.


816. Cleavage of duck hepatitis B virus envelope protein by endosomal proprotein convertase promotes viral cccDNA formation in non-susceptible LMH cells.  Y. Tong; R. Machida; S. Tong; J. R. Wands; J. Li View Pres.
Blank
Avatar_m_tn

850. Limited Value of Single ALT Determination for Assessing Chronic Hepatitis B.  E. Heathcote; P. Marcellin; I. M. Jacobson; M. L. Shiffman; H. N. Trinh; K. J. Peschell; D. Goodwin; J. Sorbel; E. A. Fagan; F. Rousseau View Pres.



853. Estimated Prevalence of Chronic Hepatitis B (CHB) in Foreign-Born (FB) Persons Living in the United States (US) by Country/Region of Origin.  S. Welch; B. Chiang; P. Shadday; C. L. Brosgart View Pres.



817. HBx protein is necessary for HBV replication in human hepatocytes..  M. Tsuge; N. Hiraga; M. Imamura; S. Takahashi; K. Chayama View Pres.



835. A previously unidentified subset of CD4-CD8-T cells contributes to the persistence of chronic viral hepatitis via virus specific killing of CD8+ T cells.  W. Yan; X. Wang; Q. Xiaoming; J. Zhang; T. Chen; H. Wang; X. Luo; Q. Ning View Pres.

849. Control of HBV replication by HepaRG cells innate response .  J. Lucifora; D. Durantel; B. Testoni; O. Hantz; M. Levrero; F. Zoulim View Pres.



840. Is liver biopsy required for all patients (pts) with HBeAg-negative (HBeAg-) chronic HBV infection and HBV DNA <20,000 IU/mL?.  G. V. Papatheodoridis; E. K. Manesis; S. Manolakopoulos; I. Elefsiniotis; I. Giannousis; G. Kafiri; A. J. Archimandritis View Pres.



830. Impact of HBV variant fitness on their selection during anti-HBV therapy.  S. Villet; G. Billioud; C. Pichoud; J. Lucifora; O. Hantz; C. C. Sureau; P. Deny; F. Zoulim View Pres.

872. Mechanism for the Dependence of Hepatitis B virus genotypes G on Coinfection with Other Genotypes for Viral Replication.  T. Sakamoto; Y. Tanaka; M. Sugiyama; F. Kurbanov; K. Matsuura; A. Kusakabe; N. Shinkai; F. Sugauchi; M. Mizokami View Pres.



847. Future Hepatitis Activation and Hepatocarcinogenesis in HBeAg-Negative HBV Carriers with Persistently Normal Alanine Aminotransferase, a Prospective Cohort Study.  T. Nakazawa; Y. Shibata; A. Takeuchi; Y. Okuwaki; K. Ono; Y. Miura; H. Hidaka; Y. Tanaka; J. Takada; M. Watanabe; A. Shibuya View Pres.



871. The Frequency of T126 in Surface Antigen Increase with Disease Progression in Patients with Chronic Hepatitis B Virus (genotype C) Infection.  C. Kim; S. Yoon; C. You; J. Jang; S. Bae; J. Choi; J. Yang; J. Han; S. Choi; N. Han; C. Lee; Y. Lee View Pres.


823. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.  S. Kamili; T. Sozzi; G. Thompson; K. Campbell; C. M. Walker; S. Locarnini; K. Krawczynski View Pres.


860. Modulation of ERK, AKT, apoptosis and cell cycle in primary mouse hepatocytes and Huh7 cells by wild-type and rtM204I HBV..  R. Chin; U. Nachbur; C. Bock; J. Silke; J. Torresi View Pres.



854. Plasmacytoid Dendritic Cell function is impaired in Chronic Hepatitis B Infection.  D. Ratnam; K. Visvanathan; P. U. Cameron; W. Sievert View Pres.

824. New insights into HBV pathogenesis from kinetic analysis of HBeAg titre decay during potent antiviral therapy..  A. J. Thompson; E. Shudo; R. Ribeiro; K. Visvanathan; P. V. Desmond; G. K. Lau; A. S. Perelson; S. Locarnini View Pres.



841. Pattern of serial HBV DNA level and HCC development in Patients with Liver Cirrhosis.  J. Kwon; J. Choi; H. Woo; J. Kim; C. You; S. Bae; S. Yoon; N. Han; C. Lee; Y. Lee View Pres
Blank
Avatar_m_tn
Just realized there are about 30 more pages so I'll try and return later with an edited version of what remains. If not, someone else please jump in. And again, if you want to read the abstracts, just register, sign in and go to it!

-- Jim
Blank
619345_tn?1310345021
Thanks that is a great amount of info to digest but there are some topics of great interest to me  I love coffee and the stronger the better I have limited my coffee intake to three strong cups a day so maybe my high intake of caffeine all my life was a good thing will check it out and more thanks again for your dilegence in always providing informative info
Blank
476246_tn?1310999221
Thanks so much Jim! As always so informative and thorough.

God bless,

Marcia
Blank
626749_tn?1256519302
Thanks for the link Jim.

So, are the doctors mentioned in the lists, part of the study/abstract, and or are they there at the meeting giving lectures on those studies?

I did not have to registrar, just went to your link, then
clicked Liver Meeting, View Itinerary Planer, then hit search.

Put my doctor in the search box, pages came up with his name, along with other very familiar big name hep dr.
If you click on the View pres, then you get the study, or is that the abstract ? and it lists all the Dr's research centers.

In some of the studies my dr was listed with other dr, some part of his local team and some not. Some studies he was listed alone. Does that mean he is there helping present those studies with the other listed dr ?

Sorry for all the questions, don't really know much about medical abstracts but find them very interesting and informative on the cutting edge of our disease.
Good stuff, and nice to see my doctors involved.

apache
Blank
Avatar_m_tn



1836. Never injected, but hepatitis C virus infected: a study among never-injecting drug users from the Amsterdam Cohort Studies.  C. van den Berg; T. J. van de Laar; A. Kok; F. Zuure; R. Coutinho; M. Prins View Pres.



1845. Incidence and risk factors for HCV superinfection and reinfection in individuals treated for acute/early chronic HCV infection.  G. Matthews; J. Grebely; P. A. White; M. K. Renkin; P. Marks; R. A. Ffrench; W. Rawlinson; J. Kaldor; M. Hellard; A. R. Lloyd; G. J. Dore View Pres.



1831. Racial Differences in Natural Killer (NK) and Natural T (NT) cells: Effect of Hepatitis C Virus (HCV) Infection..  L. Golden-Mason; N. Castelblanco; H. R. Rosen View Pres.



1837. Longitudinal incidence of liver complications and initiation of antiviral therapy among HCV-infected patients enrolled in a managed care organization (MCO).  C. Hsu; T. L. Kauf View Pres.


1835. Manganese Superoxide Dismutase Dimorphism causes hepatocellular carcinoma in cirrhotic patients with hepatitis C virus infection.  M. Korenaga; K. Korenaga; Y. Yamaguchi; K. Hino; I. Sakaida View Pres.

1843. Hepatitis C in Dialysis and Renal Transplant Patients - Analysis of the Australia and New Zealand Dialysis and Transplant Registry Reveals Significant Impact of Hepatitis C Infection After Renal Transplantation.  D. R. Scott; J. K. Wong; S. T. Spicer; H. Dent; M. T. Levy View Pres.



1833. Ethnicity is Associated with HCV Progression When Controlling for Elements of the Metabolic Syndrome.  E. R. Kallwitz; J. Layden; M. Dhamija; G. Guzman; J. L. Berkes; S. Cotler; T. J. Layden View Pres.



1832. Emergence of hepatitis C virus genotype 4 in the Netherlands: phylogenetic analysis reveals three distinct epidemiological profiles..  J. de Bruijne; J. Schinkel; M. Prins; S. M. Koekkoek; H. W. Reesink; R. Molenkamp; T. J. van de Laar View Pres.


1844. Natural history of chronic liver disease in the Dionysos cohort..  S. Bellentani; G. Bedogni; L. Miglioli; F. Masutti; S. Ferri; A. Castiglione; L. Crocè; A. Granito; M. Lenzi; C. Tiribelli View Pres.



1838. Natural History and Treatment Outcome of Acute hepatitis C With and Without HIV Co-infection in a North American Cohort.  L. M. Jones; A. J. Uriel; D. E. Kaplan; D. C. Carriero; M. E. Valiga; A. L. Klepper; R. Reddy; F. Nunes; M. P. Mullen; A. Aytaman; D. T. Dieterich; V. LoRe; I. Frank; A. D. Branch; K. Chang; D. S. Fierer View Pres.



1842. The German Hep-Net Acute Hepatitis C Cohort: Impact of viral and host factors on the course of acute hepatitis C virus infection in 259 patients.  K. Deterding; J. Wiegand; N. Grüner; M. Cornberg; E. Jäckel; M. Jung; M. P. Manns; H. Wedemeyer View Pres.


1841. The serum lipid profile and associations with liver disease and viral levels in a treatment naïve chronic hepatitis C infected cohort.  D. Ramcharran; L. J. Yee; H. S. Conjeevaram; R. Evans; A. S. Wahed; S. H. Belle View Pres.


1840. Uneven Geographic Distribution of HCV Genotypes and Higher Prevalence of Co-infection with More than One HCV Genotype in Blood Donors in China.  D. Xu; Z. Zhou; L. Wang; R. Xue; Y. Liu; X. Li; W. Zhao; J. Jiang; C. Lin View Pres.



1874. Population PK/PD modeling of eltrombopag concentration-platelet response and dose simulations for patients with chronic hepatitis C virus (HCV)-infection.  J. Zhang; D. Theodore; K. H. Moore; F. M. Campbell; D. Williams View Pres.



1889. Discovery, Design, and Characterization of Modulators of HCV Replication.  L. F. Peng; S. Kim; S. Matchacheep; N. Maloof; W. Lin; A. Beeler; J. A. Porco; S. Schreiber; R. T. Chung View Pres.


1883. PK/PD Modeling of IFN Induction Therapy for HCV: Why Induction has failed and Implications for New Therapies.  E. A. Grovender; C. Hamlen; B. Van Antwerp View Pres.


1870. Viral Kinetic Response to 12 Week Treatment with Rosiglitazone in Chronic Hepatitis C, Genotype 1 Patients Who Are Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin.  S. J. Mills; R. J. Naus; K. Barstow; S. Harrison View Pres.
Blank
Avatar_m_tn


1846. Viral Responses in African-Americans, Latinos and Caucasians in the US Phase 2 Study (PROVE1) of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Genotype 1-infected Subjects with Hepatitis C.  A. J. Muir; E. J. Lawitz; J. G. McHutchison; S. C. Gordon; I. M. Jacobson; B. S. Adiwijaya; L. Bengtsson; L. McNair; M. Rodriguez-Torres View Pres.


1894. Identification of novel HCV NS3 helicase inhibitors through the application of optimized unwinding and ATPase assays in high throughput screens (HTS).  K. Kossen; J. Kraemer; D. Winkler; T. Hesterkamp; S. Misialek; R. Rajagopalan; B. O. Buckman; L. M. Blatt; S. Seiwert; L. Beigelman View Pres.


1858. A double blind, placebo-controlled trial with escitalopram to prevent psychiatric adverse events during treatment with pegylated interferon-alpha and ribavirin for chronic hepatitis C: The “Prevention Of Psychiatric Side effects (POPS)-study”.  G. Bezemer; A. R. Van Gool; J. P. Drenth; B. E. Hansen; H. A. Droogleever Fortuyn; C. J. Weegink; M. W. Hengeveld; H. L. Janssen; R. J. de Knegt View Pres.


1900. Effects of ACE-Inhibitors on Liver Fibrosis in HIV and Hepatitis C (HCV) Co-Infection.  L. Reese; D. Tider; A. Stivala; D. A. Fishbein View Pres.


1850. Predicting the Ability to Achieve a Sustained Virologic Response (SVR) in the First 12 Weeks: Results From the IDEAL Study.  L. M. Nyberg; M. L. Shiffman; H. Bonilla; K. Hu; T. R. Morgan; R. A. Levine; E. J. Lawitz; J. G. McHutchison; A. J. Muir; G. Galler; J. McCone; W. M. Lee; R. H. Ghalib; E. R. Schiff; J. S. Galati; B. R. Bacon; M. Davis; S. K. Herrine; A. L. Gibas; B. Freilich; J. W. King; L. Rossaro; M. S. Sulkowski; P. Mukhopadhyay; S. Noviello; J. K. Albrecht; F. Poordad View Pres.


1901. PSI-7851: A Novel Liver-Targeting Nucleotide Prodrug for the Treatment of Hepatitis C.  P. A. Furman; P. Wang; C. Niu; D. Bao; W. Symonds; D. Nagarathnam; H. Micolochick Steuer; S. Rachakonda; B. S. Ross; M. J. Otto; M. Sofia View Pres.


1851. Treatment-related anemia but not epoetin use (EPO) is associated with higher SVR rates among persons treated with peginterferon (PEG)/ribavirin (RBV): Results from the IDEAL Study.  M. Sulkowski; M. L. Shiffman; N. H. Afdhal; K. Reddy; W. Deng; S. Noviello; J. K. Albrecht; J. G. McHutchison View Pres.


1868. Probability of Sustained Virologic Response (SVR) Is Associated With the Magnitude of HCV RNA Reduction at Week 4 of Treatment With Peginterferon (PEG) Plus Ribavirin (RBV): Results of the IDEAL Trial.  M. Sulkowski; J. M. Vierling; K. a. Brown; S. L. Flamm; P. Kwo; K. D. Mullen; T. D. Box; W. M. Cassidy; M. J. Ryan; M. Pauly; S. N. Joshi; D. C. Nelson; R. M. Strauss; T. D. Boyer; F. Poordad; M. Kugelmas; F. Nunes; N. Ravendhran; C. I. Smith; E. Godofsky; A. Reuben; M. L. Shiffman; W. Deng; S. Noviello; J. K. Albrecht; J. G. McHutchison View Pres.


1899. Potent Antiviral Response To The HCV Nucleoside Polymerase Inhibitor R7128 For 28 Days With Peg-Ifn And Ribavirin: Subanalysis by Race/Ethnicity, Weight and HCV Genotype.  M. Rodriguez-Torres; J. Lalezari; E. J. Gane; E. DeJesus; D. R. Nelson; G. T. Everson; I. M. Jacobson; K. Reddy; J. G. McHutchison; A. Beard; S. Walker; W. Symonds; M. M. Berrey View Pres.


1869. Hematologic safety data from the IDEAL Trial: neutropenia, anemia and thrombocytopenia profiles of Peginterferon alfa/ribavirin.  F. Poordad; N. Brau; E. J. Lawitz; M. L. Shiffman; J. G. McHutchison; A. J. Muir; G. Galler; J. McCone; L. Nyberg; W. M. Lee; R. H. Ghalib; E. R. Schiff; J. S. Galati; B. R. Bacon; M. Davis; S. K. Herrine; A. L. Gibas; B. Freilich; J. W. King; L. Rossaro; P. Mukhopadhyay; S. Noviello; C. A. Brass; J. K. Albrecht; M. S. Sulkowski View Pres.


1906. Telaprevir treatment in combination with interferon-alpha to a human hepatocyte chimeric mouse with hepatitis C virus infection.  E. Iwao; M. Imamura; N. Hiraga; T. Kimura; D. Miki; T. Hatakeyama; F. Mitsui; M. Tsuge; N. Kamiya; S. Takahashi; K. Chayama View Pres.


1884. HCV-RNA clearance in PBMC at 4 weeks predicts SVR in patients with CHC genotyap 1 and it is associated to restored IFN-γfunction..  A. Perrella; A. D'Antonio; C. Sbreglia; S. Grattacaso; M. Gnarini; O. Perrella View Pres.


1888. A Novel Sustained Release Interferon-Alpha-2b (IFN-Alpha-2bXL) With Optimized Pharmacokinetics/Pharmacodynamics Relationship vs. Pegylated Interferon-Alpha-2b (Peg-IFN-Alpha-2b): A Phase Ib Trial In HCV Patients..  C. Trepo; M. Guest; J. Grassot; R. Meyrueix; R. Rouzier; C. Raffanel; H. Belhadj-Tahar; M. Maynard-Muet; P. Berthillon; F. Nicolas; Y. Donazzolo; R. Kravtzoff View Pres.



1902. Reduction of liver stiffness by interferon treatment for chronic hepatitis C measured by transient elastography.  Y. Arima; N. Kawabe; S. Hashimoto; M. Harata; Y. Nitta; M. Murao; T. Nakano; H. Shimazaki; N. Komura; K. Kobayashi; K. Yoshioka View Pres.



1909. Identification of Novel Non-Macrocyclic Inhibitors of HCV NS3/4A Serine Protease Activity.  B. O. Buckman; L. Pan; L. Huang; K. Kossen; R. Rajagopalan; S. Misialek; S. K. Stevens; H. Tan; D. Ruhrmund; V. Serebryany; J. Matulik-Adamic; A. Stoycheva; S. Ammons; D. K. Fuhrer; L. M. Blatt; L. Beigelman; S. Seiwert View Pres.



1862. Histologic Response to Peginterferon Alfa-2a Plus Ribavirin in Treatment-Naive Latino and Non-Latino White Patients Infected With HCV Genotype 1: The LATINO Study .  L. A. Balart; F. M. Hamzeh; M. Rodriguez-Torres View Pres.



1903. Characterization of HCV inhibition by mutated IFN-alpha with increased IFN receptor binding affinity.  M. F. Sprinzl; L. Buehrer; G. Schreiber; R. Bartenschlager; P. R. Galle; J. Piehler; M. Schuchmann View Pres.



1886. Hepatitis C Virus Production is Impaired by Heat Shock Protein Synthesis Inhibitors.  O. Gonzalez; V. Fontanes; S. Raychaudhuri; V. Arumugaswami; R. Loo; J. A. Loo; R. Sun; A. Dasgupta; S. W. French View Pres.

1871. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics (PK) of Single Ascending Oral Doses of the NS3/4A Protease Inhibitor ITMN 191 in Healthy Subjects.  W. Z. Bradford; C. Rubino; S. Porter; A. Forrest; L. M. Blatt; A. A. Patat View Pres.



1913. In Vitro Activity and Pharmacological Properties of IDX375, a Novel HCV Non-Nucleoside Inhibitor.  D. N. Standring; J. P. Bilello; C. B. Dousson; J. Griffon; M. LaColla; L. Lallos; M. Liuzzi; A. Loi; J. McCarville; J. Paparin; C. Pierra; A. Roland; M. Seifer; D. Surleraux View Pres.



Blank
Avatar_m_tn
1904. Discovery of Potent and Selective Inhibitors of Hepatitis C Virus (HCV) Entry.  G. Coburn; A. Q. Han; J. de Muys; C. Gauss; K. Provoncha; M. Canfield; D. Paul; S. Mohamed; S. Moorji; D. Fisch; J. D. Murga; Y. Rotshteyn; D. Qian; P. J. Maddon; W. C. Olson View Pres.



1847. Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Patients with the NS3/4A Protease Inhibitor ITMN-191 Leads to Rapid Reductions in Plasma HCV RNA: Results of a Phase 1b Multiple Ascending Dose (MAD) Study.  N. Forestier; D. G. Larrey; D. Guyader; P. Marcellin; R. Rouzier; A. A. Patat; W. Z. Bradford; S. Porter; S. Zeuzem View Pres.


1861. Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships for ITMN-191 in a Phase 1 Multiple Ascending Dose Trial in Patients with Genotype 1 Chronic Hepatitis C (CHC)Infection .  C. Rubino; W. Z. Bradford; A. Forrest; S. Porter; L. M. Blatt; S. Seiwert; S. Zeuzem View Pres.



1893. Can RNA interference combined with interferon-a for the treatment of chronic hepatitis C?.  Q. Pan; S. D. Henry; H. J. Metselaar; B. J. Scholte; J. Kwekkeboom; H. W. Tilanus; H. L. Janssen; L. J. van der Laan View Pres.



1880. Vγ9Vδ2 T cells activated by IPH1201 (synthetic phosphoantigen) as possible immunotherapy for chronic HCV infection and its rationale for combination with IFNα.  C. Bonnafous; E. Viey; V. Scaglione-Caucig; J. Lepage; C. Agrati; F. Martini; P. Halfon; R. Buffet; H. Sicard View Pres.



1867. Influence of Insulin Resistance on Hepatic Fibrosis and Steatosis in HIV-HCV Co-Infected Compared to HCV Monoinfected Patients .  P. Halfon; G. Penaranda; F. Carrat; P. Bedossa; M. Bourliere; D. Ouzan; C. Renou; A. Tran; E. Rosenthal; C. Wartelle; P. Delasalle; P. Cacoub View Pres.



1848. Evaluation of a 4 Week Lead-In Phase with Nitazoxanide (NTZ) Prior To Peginterferon (PegIFN) Plus NTZ for Treatment of Chronic Hepatitis C: Final Report.  J. Rossignol; A. Elfert; E. B. Keeffe View Pres.

Blank
Avatar_m_tn

1859. Double-blind, randomized, placebo-controlled, multi-center, Phase II dose-ranging study to assess the antifibrotic activity of farglitazar in chronic hepatitis C infection..  J. G. McHutchison; Z. D. Goodman; H. R. Makhlouf; M. Rodriguez-Torres; M. L. Shiffman; D. C. Rockey; P. Husa; W. Chuang; D. Theodore; R. A. Brigandi; A. Webster; M. Schultz; H. A. Watson; B. Stancil; S. L. Fox; M. J. Gartland; S. D. Gardner View Pres.

1872. Short duration therapy of pegylated interferon alfa-2b plus ribavirin for HCV genotype 2 patients.  Y. Katano; M. Ishigami; I. Nakano; K. Hayashi; T. Honda; H. Goto View Pres.


1856. No Compensatory Fitness Mutations Selected in NS3/4A Protease Cleavage Sites During Treatment with Telaprevir, Peg-IFN-Alfa-2a, and Ribavirin in Phase II Studies of Treatment-Naïve HCV Genotype 1-Infected Patients.  E. Z. Zhang; D. J. Bartels; J. Sullivan; M. Marcial; J. Dorrian; A. Tigges; A. D. Kwong; T. L. Kieffer View Pres.


1873. A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) has a favorable risk:benefit ratio in non-responders to pegylated interferon alfa-2b (12KD) plus ribavirin: findings of the multinational REPEAT study.  P. Marcellin; A. Craxi; C. E. Brandão-Mello; A. M. Di Bisceglie; P. Andreone; B. Freilich; K. Reddy; A. Olveira; G. Teuber; D. Messinger; G. Hooper; J. A. Thommes; D. M. Jensen View Pres.


1907. Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection.  K. Steffy; L. Kirkovsky; R. E. Lanford; R. E. Showalter; M. Sergeeva; J. Zhao; D. R. Averett; J. R. Appleman View Pres.


1910. Safety, Tolerability, and Pharmacokinetic Data Following Single- and Multiple-Dose Administration of MK-7009, a Hepatitis C Virus Non-structural 3/4a Protease Inhibitor, to Healthy Male Subjects.  D. Wright; J. L. Miller; I. Verlinden; C. Cilissen; J. Valentine; P. Sun; M. De Smet; J. de Hoon; M. Depré; L. Cavens; J. Chodakewitz; J. A. Wagner View Pres.


1898. Safety, Tolerability and Pharmacokinetics of the HCV Polymerase Inhibitor PF-00868554 Following Multiple Dose Administration in Healthy Volunteers.  J. L. Hammond; V. S. Purohit; J. Fang; M. F. DeBruin View Pres.



1849. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype-1 infection given as monotherapy and in combination with Peginterferon alfa 2a (P) and Ribavirin (R).  M. P. Manns; M. Bourliere; Y. Benhamou; S. Pol; M. Bonacini; T. Berg; C. Trepo; D. Wright; J. L. Calleja; G. Steinmann; D. B. Huang; J. Mikl; G. Kukolj; J. O. Stern View Pres.


1896. Enhancement of autocrine interferon-beta and decrease in SOCS-3 by ME3738 contribute to synergistic anti-HCV effects when combined with interferon-alpha.  Y. Hiasa; Y. Tokumoto; I. Konishi; K. Michitaka; M. Onji View Pres.



1882. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in combination therapy with Peginterferon alfa 2a (P) and Ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype-1 infection..  M. P. Manns; M. Bourliere; Y. Benhamou; M. Schuchmann; D. Haussinger; S. Pol; M. Bonacini; G. Steinmann; D. B. Huang; J. Mikl; G. Kukolj; J. O. Stern View Pres.


1885. Combination of the NS3/4A Protease Inhibitor ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors R1626 or R7128 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants .  H. Tan; S. Rajyaguru; T. Wu; M. McCown; S. Ali; W. Jiang; M. J. Otto; P. A. Furman; I. Najera; K. Klumpp; J. Symons; N. Cammack; L. M. Blatt; S. Seiwert View Pres.

1897. Genotypic and phenotypic analysis of Hepatitis C Virus NS5B polymerase variants to BILB 1941 inhibition.  M. Marquis; K. Deterding; A. Erhardt; Y. Benhamou; C. Moelleken; X. Forns; S. Pol; J. Calleja; S. Ross; H. Spangenberg; C. Toro; M. Fuchs; J. Enríquez; J. Wiegand; P. Beaulieu; G. Nehmiz; J. Steffgen; J. O. Stern; G. Kukolj View Pres.


1914. A small molecule inhibits HCV replication by disrupting NS4B localization.  P. D. Bryson; N. Cho; S. Einav; C. Lee; V. Tai; J. Bechtel; M. Sivaraja; C. D. Roberts; U. Schmitz; J. S. Glenn View Pres.

1908. In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance.  P. A. Thompson; R. Patel; R. E. Showalter; C. Li; J. R. Appleman; K. Steffy View Pres.


1863. Intravenous silibinin for treatment of nonresponders to peginterferon/ribavirin therapy in chronic hepatitis C.  P. Ferenci; T. Scherzer; H. Kerschner; K. Rutter; S. Beinhardt; H. Hofer; M. Schöniger-Hekele; H. Holzmann; P. E. Steindl-Munda View Pres.


1890. Cyclosporine in HCV-non responders: a cytoprotective effect without antireplicative action. A phase II study. .  P. Lebray; J. Moussalli; D. Thabut; V. Ratziu; T. Poynard; Y. Benhamou View Pres.


1877. Relationship between immunocompetent cells as natural killer and dendritic cells with response to anti-hepatitis C viral therapy.  M. Andrieu; J. Gaston; E. Middendorp; V. Mallet; M. Nascimbeni; L. Vimeux; M. Ahloulay; S. Fernandes; A. Vallet-Pichard; B. Nalpas; S. Pol View Pres.


1875. IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND RVR 14 WEEKS TREATMENT IS NON-INFERIOR TO 24 WEEKS. POOLED ANALYSIS OF TWO SCANDINAVIAN TRIALS .  O. Dalgard; H. Verbaan; H. Ring-Larsen; K. Bjøro View Pres.



1876. Efficacy and safety of an intensified regimen of pegylated interferon alfa-2a plus ribavirin in HCV genotype 1-infected patients who did not respond to a prior standard regimen of pegylated interferon alfa-2a plus ribavirin: an interim analysis of the multicentric, randomized, controlled SYREN trial.  C. Hezode; J. Foucher; J. Bronowicki; V. Leroy; A. Tran; D. G. Larrey; P. Mathurin; I. Rosa; L. Alric; V. Dhalluin-Venier; A. Nani; M. Bouvier-Alias; S. Rouanet; P. Couzigou; A. Mallat; A. Pinta; J. Pawlotsky View Pres.


1878. Non-Responder HCV Genotype 2/3 Patients: Is It Simply A Question of Suboptimal Interferon And Ribavirin Concentrations?.  Å. Alsiö; P. B. Christensen; P. D. Leutscher; M. A. Färkkilä; . Mørch; M. Buhl; C. Pedersen ; N. Lagenland; J. Westin; K. Hellstrand; G. P. Norkrans; M. Lagging View Pres.


1853. Refined prediction of week 12 response and SVR based on the virological response at week 4 in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®).  P. Marcellin; N. Reau; P. Ferenci; D. M. Jensen View Pres.

Blank
Avatar_m_tn

1864. Pharmacokinetics (PK) of ribavirin (RBV) in patients with renal impairment or end-stage renal disease (ESRD) and chronic hepatitis C (CHC) during treatment with peginterferon alfa-2a (40KD) (PEGASYS®) and RBV (COPEGUS®).  K. Wang; A. A. Lawal; M. Majchrowicz; P. N. Morcos; S. Moreira; S. A. Draibe; R. H. Ghalib; A. Zaman; J. S. Crippin; V. Joshi; P. Martin; J. Grippo View Pres.


1895. Pharmacokinetics of once-daily regimens of the novel HCV NS3/4A-protease inhibitor TMC435350, with and without pegIFN and ribavirin, in HCV-infected individuals.  G. A. van 't Klooster; I. Vanwelkenhuysen; R. Verloes; K. Marien; P. Van Remoortere; K. Simmen View Pres.


1865. Levels of FGL2/Fibroleukin an effector of CD4+CD25+Treg Cells Predicts Course of Chronic Hepatitis C disease.  N. Selzner; Y. Zhu; O. Adeyi; I. Shalev; R. Khattar; E. Heathcote; G. A. Levy View Pres.


1855. Prediction of SVR in HCV genotype 1 patients co-infected with HIV based on virological responses at week 4 and 12 of treatment with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®): Retrospective analysis of APRICOT.  M. Rodriguez-Torres; J. Rockstroh; J. Depamphilis; G. Carosi; D. T. Dieterich; F. Torriani View Pres.

1857. Taribavirin Exposure Analysis from a Previous Phase 3 Trial Correlates with Phase 2b Weight Based Dosing Interim Results .  P. Pockros; I. M. Jacobson; B. R. Bacon; N. H. Afdhal; F. Poordad; E. Chun; J. Hammond View Pres.


1912. Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6.  T. Lin; B. Devogelaere; O. Lenz; O. Nyanguile; E. Van Der Helm; K. Vermeiren; G. Vandercruyssen; E. Cleiren; J. Lindberg; M. Edlund; P. J. Raboisson; H. de Kock; M. D. Cummings; G. Fanning; K. Simmen View Pres.

1887. Characterization of a new amino acid substitution (V36C) associated with telaprevir (VX-950) resistance in a patient treated with telaprevir, peginterferon alpha-2a and ribavirin.  L. Barbotte; A. Ahmed-Belkacem; S. Chevaliez; A. Soulier; C. Hezode; J. Pawlotsky View Pres.


1879. Neurocytokynes changes inducing Peg-interferon-alpha depression: a rational approach to increase adherence of therapy in Chronic Hepatitis C. .  L. Cavalletto; A. Bertazzo; G. Ferri; E. Bernardinello; S. Comai; P. Amodio; D. Sterrantino; G. I. Perini; A. Gatta; L. Chemello View Pres.


1860. High sustained virologic response rates in HCV genotype 1 relapser patients retreated with peginterferon alfa-2a (40KD) plus ribavirin for 72 weeks.  S. Kaiser; B. Lutze; H. G. Hass; C. R. Werner View Pres.


1854. Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon-Alfa-2a or -Alfa-2b and Ribavirin in Treatment-Naïve Subjects with Genotype 1 Hepatitis C: Week 4 Interim Results.  X. Forns; P. Marcellin; T. Goeser; P. Ferenci; F. Nevens; G. Carosi; J. P. Drenth; K. De Backer; R. van Heeswijk; T. J. Vangeneugden; G. Picchio; M. Beumont-Mauviel View Pres.


1852. A Study of Telaprevir Combined with Peginterferon-Alfa-2a and Ribavirin in Subjects with Well-Documented Non-Response or Relapse after Previous Peginterferon-Alfa-2a and Ribavirin Treatment: Interim Analysis.  M. L. Shiffman; T. Berg; F. Poordad; J. Bronowicki; A. J. Muir; S. C. Gordon; S. George; N. Adda; J. G. McHutchison View Pres.


1911. Biochemical Characterization of GL60667 (LDI133), a Potent Non-Nucleoside Inhibitor of the HCV RNA-Dependent RNA Polymerase..  J. Pouliot; R. N. Pagila; K. Fung; G. Deng; G. Chenail; D. R. Latour; J. Zhang; S. Koo-McCoy; M. Sivaraja; J. Bechtel; K. Lin; J. Gralapp; S. G. Alvarez; M. Leivers; U. Schmitz; T. Compton; R. Griffith View Pres.

1915. The Discovery of Novel, Non-immunosuppressive Cyclosporin Ethers, and Thioethers with Potent HCV Activity.  M. Peel; R. Harris; Z. Huang; M. G. Murray; K. Li; T. E. Richardson; B. Scorneaux; A. Scribner; S. A. Wring View Pres.


1892. Niacin but not simvastatin is associated with reduced Hepatitis C RNA titers: A Cross-Sectional Analysis.  K. A. Forde; C. Law; R. M. O'Flynn; D. E. Kaplan View Pres.


1881. Nitazoxanide (NTZ) is an inducer eIF2a and PKR phosphorylation .  M. Elazar; M. Liu; S. McKenna; P. Liu; E. A. Gehrig; A. Elfert; J. Puglisi; J. Rossignol; J. S. Glenn View Pres.


1891. In Chronic Hepatitis C (HCV), Pretreatment with Thiazolidinediones (TZDs) or Metformin Decreases Insulin Resistance (IR) and HCV Viral Load and Increases Early Virologic Response (EVR).  M. Adler; J. L. Matloff; A. S. Boxer; H. Han; M. Vachon; D. C. Carriero; D. T. Dieterich View Pres.



1905. Heme oxygenase-1 reaction products suppress Hepatitis C virus replication in full length and non-structural replicon cell lines.  Z. Zhu; A. T. Wilson; K. Brown; B. A. Luxon; W. N. Schmidt View Pres.


1866. Treatment of Peginterferon/Ribavirin Nonresponders with daily Dosing of Consensus Interferon and Ribavirin: Results from the German Consensus Interferon Multicenter Study .  S. Kaiser; B. Lutze; H. G. Hass View Pres.



1286. Specific joint hepatology–addiction medicine follow-up of hepatitis C treatment for intravenous drug users (IDU) or ex-IDU improves treatment response .  G. Anne; G. Laurent; B. Vincent; A. Jean-Pierre; B. Celine; J. Jacques View Pres.


1252. Determinants of HCV Antiviral Treatment in a Managed Care Setting.  M. Manos; V. Shvachko; W. Zhao; R. C. Murphy View Pres.
Blank
Avatar_m_tn

1303. NK cell activity predicts rapid and early virological response in interferon therapy against HCV infection.  Y. Haruna; A. Inoue View Pres.


1235. HEPATIC TRANSCRIPTIONAL RESPONSES OF TLR3/RIG-I SIGNALING TO HCV REPLICATION: SIGNIFICANCE IN PEGINTERFERON PLUS RIBAVIRIN TREATMENT.  N. Yuki; S. Matsumoto; M. Kato; T. Yamaguchi View Pres.


1321. Effectiveness of Hepatitis C Treatment with Pegylated Interferon and Ribavirin in an Urban Patient Population .  A. L. Bunim; J. Karlitz; H. Massoumi; E. Garcia; A. J. Thosani; A. Pellecchia; P. J. Gaglio; J. F. Reinus View Pres.



1273. Asian Ethnicity is a Significant Predictor of Sustained Virologic Response (SVR) to Combination Therapy with Peginterferon (PEG IFN) and Ribavirin (RBV) in Chronic Hepatitis C (CHC).  P. Vutien; N. H. Nguyen; R. T. Garcia; H. N. Trinh; L. H. Nguyen; E. B. Keeffe; G. Garcia; K. K. Nguyen; H. A. Nguyen; B. S. Levitt; M. H. Nguyen View Pres.


1274. Current Opinion Regarding the Utilization of Liver Biopsies in the Management of Hepatitis C: A National Survey.  D. J. Weinerman; R. Chadalavada; K. D. Mullen View Pres.

1234. Proteomic Profiling of Serum using SELDI-TOF MS in Hepatitis C (HCV) infected individuals on treatment with Pegylated Interferon-α and Ribavirin.  E. J. Devitt; K. A. Power; J. A. Browne; W. M. Gallagher; J. P. Crowe View Pres.

1236. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies non responders to peginterferon-ribavirin combination therapy after 4 weeks of treatment..  H. Orlent; I. Desombere; B. E. Hansen; H. Van Vlierberghe; B. Haagmans; R. J. de Knegt; S. W. Schalm; G. Leroux-Roels; H. L. Janssen; D. Study Group View Pres.


1259. Steatosis, Insulin resistance, Iron overload, Fibrosis and Viral load as negative factors affecting Early (EVR) and Sustained (SVR) Virological Response in patients with Chronic Hepatitis C treated with peginterferon and ribavirin.  E. F. Georgescu; R. Ionescu; G. Florescu; G. Mateescu; L. Vancica View Pres.


1272. Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using the Abbott RealTime HCV assay and the Roche Cobas TaqMan HCV assay..  K. Matsuura; Y. Tanaka; I. Hasegawa; T. Ohno; H. Tokuda; F. Sugauchi; s. nojiri; M. Mizokami View Pres.

1306. Predictors of nonresponse in genotype 1 patients treated with PegIFN-alfa2b and ribavirin due to chronic hepatitis C within a large German multicentric observational study..  D. Hueppe; E. Zehnter; S. Mauss; M. P. Manns; G. Teuber; T. Dahhan; S. Kaiser; U. Meyer; T. Witthöft; R. Mendel; B. Moeller; N. Dikopoulos; J. Brack; M. Bilzer; G. Tossing View Pres.


1289. Serum total and LDL cholesterol, the metabolic syndrome and oxidative stress are independent predictors of rapid virological response in HCV patients.  F. Angelico; S. Francioso; K. Feole; M. Del Ben; R. Carnevale; M. Carbone; M. Angelico; F. Violi View Pres.


1290. A retrospective comparative study of Pegylated interferon and ribavirin for the treatment of chronic hepatitis C genotype 6 and genotype 1.  O. T. Tsang; J. Zee; J. Chan; R. S. Li; J. Lai; T. S. Lai View Pres.

1322. Interferon and ribavirin combination therapy in patients with hepatitis C related hepatocellular carcinoma .  S. Shin; S. Paik; H. Jung; G. Gwak; M. Choi; J. Lee; K. Koh; B. Yoo View Pres.

1251. Very Low Viral Load (VLVL) Relapse after Treatment for HCV: A unique group with High Sustained Virologic Response (SVR) to low dose, Short Course Retreatment.  J. C. Hoefs; V. S. Aulakh View Pres.


1333. Efficacy of Chronic Hepatitis C (CHC) Treatment in an Urban, County Hospital Population Using Strict Screening Criteria.  T. D. Dharia; P. F. Malet; J. Cuthbert View Pres.

1309. Importance of prior psychiatric consultation in pegylated interferon and ribavirin combination therapy for chronic hepatitis C .  K. Kuhara; T. Ide; N. Uchimura; R. Kumashiro; T. Arinaga; K. Ogata; R. Kuwahara; I. Miyajima; M. Sata View Pres.

1288. Does the platelet count influence treatment success in patients with Hepatitis C?.  A. Lawson; A. Austin; G. Harrison; K. Neal; S. D. Ryder; W. Irving View Pres.


1225. Inhibition of hepatitis C virus replication by interferon stimulated genes: the contrastive role of MxA, PKR, and OAS in interferon treatment.  J. Chang; N. Kato; R. Muroyama; T. Kawabe; M. Omata View Pres.


1325. Outcomes of Antiviral Therapy for Hepatitis C in Day to Day Clinical Practice.  K. R. Muller; R. Wundke; R. K. Altus; A. Rodgers; A. J. Wigg View Pres.


1331. Baseline interleukin-18 / interleukin 10 ratio is an independent predictor of SVR patients treated with IFN-based therapy.  K. Ishii; K. Higami; M. Sawa; T. Matsui; H. Nagai; Y. Sumino View Pres.

1337. Recent Trends on Indications and Methods of Liver Biopsy.  M. J. Lipp; L. S. D'Souza; D. J. Clain; H. C. Bodenheimer; A. D. Min View Pres.


1308. Gene expression involving innate immunity and hepatitis C virus mutation in resistance to peginterferon alfa-2b plus ribavirin treatment.  Y. Asahina; I. Hirayama; T. Tanaka; M. Sato; Y. Yasui; N. Tamaki; N. Umeda; T. Hosokawa; K. Ueda; H. Ikeda; K. Tsuchiya; H. Nakanishi; J. Itakura; M. Kurosaki; S. Maekawa; N. Enomoto; N. Izumi View Pres.



1292. The predictive model for sustained viral response in peg-interferon and ribavirin therapy for hepatitis C virus genotype 1b patients is a useful marker for determine continuation and cessation of the therapy.  S. Tada; H. Saito; H. Ebinuma; K. Ojiro; Y. Yamagishi; T. Hibi View Pres.


1336. Insulin resistance, LDL cholesterol and results of hepatitis C treatment. .  M. Lebouvier; A. Minello; A. Poussier; B. Bouillet; V. Jooste; M. Guignard; J. Petit; P. Hillon View Pres.


1275. Patients with low serum albumin levels due to advanced cirrhosis are at high risk of liver failure during antiviral treatment for chronic hepatitis C.  B. J. Veldt; E. Heathcote; H. Wedemeyer; J. Reichen; W. Hofmann; S. Zeuzem; M. P. Manns; B. E. Hansen; S. W. Schalm; H. L. Janssen View Pres.

1218. MicroRNA-196 Represses Bach1 and Hepatitis C Viral NS5A Protein Expression in Human Hepatocytes Expressing HCV Non-Structural Proteins.  W. Hou; Q. Tian; J. Zheng; H. L. Bonkovsky View Pres.


1214. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.  K. Hayashi; Y. Katano; M. Ishigami; I. Nakano; H. Goto; H. Toyoda; T. Kumada View Pres.


1240. Both Sustained Virological Response (SVR) and relapse may be predicted with HCV RNA levels at second week by TaqMan HCV assay.  Y. Karino; J. Toyota; J. Akaike; M. Kimura; T. Arakawa; Y. Kuwata; I. Ozeki; K. Yamazaki; T. Sato; T. Ohmura View Pres.

Blank
Avatar_m_tn
1334. Does steatosis influence the effect of therapy and the progression of chronic liver disease caused by HCV?.  K. Tokushige; H. Noto; S. Yatsuji; M. Taniai; E. Hashimoto; K. Shiratori View Pres.


1287. Effect of IFN-β for Patients With Chronic Hepatitis C discontinuing IFN-α Therapy.  M. Shimada; S. Yoshida; Y. Kitamura; M. Yoshino; M. Yamada; M. Tsuchishima; H. Kawahara; S. Takase View Pres.


1311. PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY.  J. Sasadeusz; G. J. Dore; I. Kronborg; D. A. Barton; M. Yoshihara; M. Weltman View Pres.

1285. Peripheral blood monocyte IFNAR-2 expression predicts an early viral response in chronic hepatitis C patients treated with PEG-IFN plus ribavirin.  K. Higami; K. Ishii; M. Sawa; Y. Sumino View Pres.


1222. Impact of the use of drugs and substitution treatments on the antiviral treatment of chronic hepatitis C (HCV): analysis of compliance, virological response and quality of life (Cheobs).  P. Melin; J. Lang ; D. Ouzan; M. Chousterman ; M. Varastet; M. Rotily ; T. Fontanges ; P. Marcellin; P. Cacoub View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1261. The Impact Of A Multi-Disciplinary Support Program On Adherence And The Efficacy Of Hepatitis C Treatment.  M. Garcia-Retortillo; I. Cirera; M. Giménez; C. Marquez; J. Galeras; P. Castellví; R. Navinés; E. Clot; E. Salas; F. Bory; R. Martín-Santos; R. Solà View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1226. Evaluation of Pegylated Interferon plus Ribavirin-induced Selection and prevalence of Amino acid 70Q in Core of HCV-1b .  F. Kurbanov; Y. Tanaka; K. Matsuura; F. Sugauchi; T. Sakamoto; I. Hasegawa; T. Ohno; M. Mizokami View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1277. Apolipoprotein B associated cholesterol level is a predictor of response to therapy in Chronic Hepatitis C.  D. A. Sheridan; D. A. Price; M. L. Schmid; P. T. Donaldson; G. L. Toms; D. Neely; M. F. Bassendine View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1241. Interferon therapy for hepatitis C patients curatively treated for hepatocellular carcinoma with percutaneous therapies.  T. Goto; H. Yoshida; R. Tateishi; K. Enooku; E. Goto; H. Yoshida; T. Sato; T. Ohki; R. Masuzaki; J. Imamura; N. Yamashiki; F. Kanai; K. Hamamura; S. Shiina; T. Kawabe; M. Omata View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1326. Short-term prolongation of Peginterferon plus ribavirin combination therapy is an effective treatment strategy for genotype 1b chronic hepatitis C patient.  N. Yamada; M. Suzuki; C. Okuse; H. Ikeda; M. Okamoto; M. Kobayashi; H. Takahashi; K. Matsunaga; N. Matsumoto; H. Yotsuyanagi; K. Yasuda; S. Iino; F. Itoh View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1260. Monitoring virologic on treatment response to predict treatment outcome in patients with chronic hepatitis C treated with pegylated interferon plus ribavirin: realtime PCR assays and bDNA/TMA provide the same performances..  M. Martinot-Peignoux; S. Maylin; H. Khiri; L. Leclere; M. Ripault; P. Marcellin; P. Halfon View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1278. Relevance between fibrosis and response to treatment with Peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study..  A. Kolakowska-Rzadzka; H. Berak; M. Wasilewski; A. Horban View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1242. Sustained Virological Response in Patients with Chronic Hepatitis C is Similar Between Whites and Non-Whites: Evaluation Using Specific Ancestry Alleles Analysis in an Admixed Population..  L. N. Cavalcante; K. Abe-Sandes; A. D. Angelo; D. C. Lemaire; L. S. Souza; E. S. Azevedo; J. d. Carvalho; T. M. Machado; P. S. Brandão; N. P. Santana; L. G. Lyra; A. C. Lyra View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1295. SUSTAINED VIROLOGIC RESPONSE IS ASSOCIATED WITH WORSE QOL DURING AND IMPROVED QOL AFTER TREATMENT WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN .  M. von Wagner; W. Hofmann; G. Teuber; T. Berg; T. Goeser; U. Spengler; H. Hinrichsen; H. Weidenbach; G. Gerken; M. P. Manns; P. Buggisch; E. Herrmann View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1293. Viral Response at 4 weeks into therapy with PegIFN-alpha and Ribavirin in Chronic Hepatitis C - Correlation with BMI and Weight.  N. C. Ravindran; T. Mazzulli; D. K. Wong; E. Heathcote View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1223. Interferon-γ Inducible Protein-10 (IP-10) is a Unique Cytokine Predictor of Sustained Virological Response to Peginterferon and Ribavirin in African American and Caucasian American Patients with Chronic Hepatitis C.  M. W. Fried; C. D. Howell; M. L. Hudson; J. Bollekens; J. Aerssens; M. De Wit; A. Scholliers; G. Fanning View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1340. Durability of Sustained Virologic Response in Combination Therapy with Interferon/Peginterferon and Ribavirin for Chronic Hepatitis C .  J. Lee; J. Lee; Y. Kim; Y. Shin; D. Lee; H. Kim; S. Jeong; H. Park; H. Park; S. Hong View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1296. There were no significant difference of clinical outcomes between Peginterferon alpha 2a and 2b among patients with naive chronic hepatitis C in the middle area of South Korea: Multicenter study. Byung Seok Lee M.D1, Seok hyun Kim M.D1, ,Jeong Il Kim M.D1 Heon young Lee M.D1, Tae Hui Lee M.D2, Young Woo Kang M.D2, Hyang Yi Lee M.D3, Hyun Woong Yang M.D3, An NA Kim M.D3, Youn Soo Kim M.D4, Soon Woo Nam M.D4, Byung Chool Park M.D5, Hui Bok Chae M.D5, Seok Bae Kim M.D6, Il Han Song M.D6, Ji young Park M.D7, Hong Soo Kim M.D7. Chungnam national university hospital1, Konyang university hospital2, Eulji university hospital3, Catholic university Daejon hospital4, Chungbuk national university hospital5, Dankook university hospital6, Sooncheonhyang university Cheonan hospital7. .  B. Lee View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1282. Effect of Interferon alfa-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis .  M. Kurokawa; N. Hiramatsu; T. Takehara; T. Oze; T. Yakushijin; T. Igura; K. Mochizuki; K. Imanaka; M. Oshita; H. Hagiwara; E. Mita; T. Hijioka; Y. Inui; K. Katayama; H. Yoshihara; Y. Imai; M. Kato; S. Kiso; T. Kanto; A. Kasahara; N. Hayashi View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1294. Leuco-, Neutro- and thrombopenia during antiviral treatment with pegylated interferon-a2b (PegIFN-a2b) and ribavirin in treatment naïve patients with chronic Hepatitis C: Impact on sustained virologic response rates in a real-live scenario.  G. Teuber; D. Hueppe; S. Mauss; E. Zehnter; M. P. Manns; T. Dahhan; S. Kaiser; U. Meyer; T. Witthöft; R. Mendel; B. Moeller; N. Dikopoulos; J. Brack; R. Prinzing View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1258. Substitution of core amino acid 91 lowers rapid virolgical response and substitution of core amino 70 lowers sustained virological response to PEGinterferon alfa-2b plus Ribavirin in chronic hepatitis C patients with genotype 1b-nationwide study .  T. Okanoue; Y. Itoh; H. Yotsuyanagi; E. Tanaka; K. Yoshioka; N. Izumi; H. Kumada View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1245. Heme oxygenase 1 interfers with HCV replication in vitro.  G. Sass; M. Ocker; G. Tiegs View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected
Blank
Avatar_m_tn

1239. Are there differences in treatment outcomes between HCV genotype 2 and 3 patients with advanced fibrosis treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®)?.  S. Bruno; S. J. Hadziyannis; M. L. Shiffman; D. Messinger; P. Marcellin View Pres.


1307. Impact of pegylated bitherapy on morbidity and mortality in patients with chronic hepatitis C and normal transaminases.  S. Deuffic-Burban; I. Lonjon-Domanec; G. Babany; P. Deltenre; A. Louvet; V. Canva; S. Dharancy; H. Castel; F. Rhoudot-Thoraval; P. Mathurin View Pres.


1238. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with chronic hepatitis C responding to pegylated interferon alfa-2b plus ribavirin..  T. Oze; N. Hiramatsu; T. Yakushijin; Y. Inoue; T. Igura; K. Mochizuki; K. Imanaka; A. Kaneko; M. Oshita; H. Hagiwara; E. Mita; T. Nagase; T. Ito; Y. Inui; T. Hijioka; K. Katayama; H. Yoshihara; Y. Imai; M. Kato; Y. Yoshida; T. Tatsumi; K. Ohkawa; S. Kiso; T. Kanto; A. Kasahara; S. Tamura; T. Takehara; N. Hayashi View Pres.

1250. Detection of HCV-RNA in serum after ultracentrifugation is able to predict relapse in sustained responders .  J. Bartolomé; I. Castillo; J. Quiroga; G. Barril; V. Carreño View Pres.


1227. High rates of sustained virological response in HCV-infected injection drug users receiving directly observed therapy with peginterferon alfa-2a and once daily ribavirin.  M. Waizmann; K. Wolle; F. Ackermann View Pres.


1313. Split 24 Weeks Treatment Course of Peginterferon plus Ribavirin in Patients with Genotype 1 Chronic Hepatitis C.  J. Park; K. Yoon; M. Kim; D. Kim; S. Ahn; Y. Paik; K. Lee; B. Moon; Y. Moon; C. Chon; K. Han View Pres.

1280. Probability of virological relapse during follow-up varies with the rapidity of the on-treatment virological response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.  M. L. Shiffman; M. W. Fried; S. J. Hadziyannis; D. Messinger; P. Ferenci View Pres.



1224. Extended treatment with peginterferon alfa-2b and ribavirin combination therapy can suppress the relapse rate after treatment of chronic hepatitis C genotype 1 patients with late viral response..  T. Oze; N. Hiramatsu; T. Yakushijin; M. Kurokawa; T. Igura; K. Mochizuki; K. Imanaka; A. Yamada; M. Oshita; H. Hagiwara; E. Mita; T. Ito; Y. Inui; T. Hijioka; H. Yoshihara; E. Hayashi; A. Inoue; Y. Imai; M. Kato; Y. Yoshida; T. Tatsumi; K. Ohkawa; S. Kiso; T. Kanto; A. Kasahara; S. Tamura; T. Takehara; N. Hayashi View Pres.


1339. IS THE LIVER BIOPSY THE REFERENCE METHOD TO ASSESS FIBROSIS REGRESSION IN PATIENTS WITH HEPATITIS C VIRUS-RELATED SEVERE FIBROSIS?.  A. Abergel; M. Chevallier; S. Ughetto; C. Bonny; S. Dubost; N. Martineau; G. Bommelaer; C. Darcha View Pres.


1255. Apoptotic effects and ALT decrease by ribavirin for patients with chronic hepatitis C..  S. Hige; K. Ogawa; H. Horimoto; T. Kohara; M. Nakanishi; M. Chuma; A. Nagasaka; M. Asaka View Pres.


1253. Assessment of serum HCV RNA at week 12 post-treatment is as relevant as week 24 to predict SVR in patients with chronic hepatitis C treated with Pegylated interferon plus ribavirin .  M. Martinot-Peignoux; M. Ripault; S. Maylin; L. Leclere; N. Boyer; P. Marcellin View Pres.


1228. CF102 an A3 Adenosine Receptor Agonist Acts as a Potent Inhibitor of Hepatitis C Virus Replication and has Excellent Pharmacokinetic Properties.  S. Bar Yehuda; K. Kahalili ; R. Tur-Kaspa; S. Stemmer; R. Zemel; L. Bachmatov; A. Ochaion; S. Cohen; J. Otti; R. Patoka; P. Fishman View Pres.



1229. Virological Response to Treatment with Pegylated Interferon alfa-2b and ribavirin chronic hepatitis C in Children.  M. Pawlowska; M. Pilarczyk; W. Halota; E. Jendryczka View Pres.

1244. MUTATIONS IN CORE REGION AND NS5A OF HEPATITIS C VIRUS CORRELATES WITH THE RESPONSE TO PEG-IFN ALFA-2B PLUS RIBAVIRIN TREATMENT.  N. Kawabe; M. Murao; S. Hashimoto; M. Harata; Y. Nitta; T. Nakano; H. Shimazaki; Y. Arima; N. Komura; K. Kobayashi; K. Yoshioka View Pres.



1335. Psychopathological Changes and Quality of Life in HCV-Infected, Opioid-Dependent Patients During Maintenance therapy.  A. Schaefer; H. Wittchen; J. Siegert; M. R. Kraus View Pres.



1231. Serum concentrations of Ribavirin and Pegylated Interferon and early virological response in patients infected with HCV.  F. Nicot; L. Alric; K. Barange; S. Métivier; J. Dramard; J. Combis; B. Castan; J. Meurisse; J. Payen; D. Garipuy; H. Desmorat; J. Peron; S. THebault; T. Morin; C. Renou; P. Barel; B. Guerin; Y. Imbert; S. Sire; K. Saune; E. Chatelut; J. Izopet View Pres.



1304. Anemia during Peginterferon-Ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis.  A. Aghemo; L. Ronzoni; M. Rumi; S. Monico; A. Colancecco; P. Grillo; M. Viganò; M. D. Cappellini; M. Colombo View Pres.


1279. LYMPHOCYTOSIS AS A PREDICTOR OF POOR RESPONSE IN TREATMENT OF HEPATITIS C VIRUS.  A. Martinez-Camacho; V. Khaoustov; E. Adam; B. Yoffe View Pres.

Blank
Avatar_m_tn

1314. Long-term efficacy of peginterferon with ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related advanced fibrosis.  K. Chang; C. Lee; J. Wang; C. Hung; T. Hu; S. Lu View Pres.


1283. Multiple logisitic regression analysis identifies ribavirin as a modifiable and independent predictor of relapse amongst chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.  R. Reddy; D. T. Dieterich; S. J. Hadziyannis; D. Messinger; M. W. Fried View Pres.


1266. EDUCATION PROGRAM (EP) IMPROVES THE RATE OF SUSTAINED VIROLOGIC RESPONSE (SVR) TO ANTI-HCV THERAPY: MULTIVARIATE ANALYSIS FROM A FRENCH NETWORK EXPERIENCE.  E. Collin; S. Fratté; A. Baudu; M. Thévenot; T. Thévenot; E. Monnet; V. Di Martino View Pres.


1268. Prospective randomized study of antiviral therapy post-transplantation: effect of the type of pegylated IFN and baseline immunosuppression..  C. Ortiz; F. Lopez-Labrador; R. Canada; B. Risalde; V. Aguilera; M. Prieto; M. Berenguer View Pres.


1297. Impact of Recent Substance Use on Antiviral Treatment for Chronic Hepatitis C.  A. Knott; E. Dieperink; J. Durfee; S. B. Ho View Pres.



1298. EFFECT OF SUSTAINED VIROLOGICAL RESPONSE TO PEGINTERFERON PLUS RIBAVIRIN THERAPY ON LIVER RELATED FREE SURVIVAL IN HCV CIRRHOTIC PATIENTS. FACTORS PREDICTING VIROLOGICAL RESPONSE..  S. Alonso; D. Rincón; R. Bárcena; M. Serra; M. Romero-Gómez; I. Fernández; B. Cuenca; J. García-Samaniego; R. Planas; J. Fuentes; R. Moreno-Otero; J. C. Erdozain; R. Solá; J. F. Avilés; M. Diago; A. Poyato; C. M. Fernández-Rodriguez View Pres.


1291. HIV/HCV Co-Infected Virologic Responders To Pegylated IFN And Ribavirin Therapy More Frequently Suffer IFN-Related Adverse Events.  A. Osinusi; J. J. Rasimas; R. Bishop; M. McLaughlin; M. A. Polis; H. Masur; S. Kottilil View Pres.


1220. Anti-viral therapy in haemodialyzed HCV patients: efficacy, tolerance and treatment strategy .  P. Deltenre; D. Thabut; A. Tran; H. Castel; M. El Nady; V. Canva; A. Louvet; H. Ben Ali; F. Provot; F. Glowacki; S. Dharancy; F. Stanke; J. Henrion; C. Noel; P. Mathurin View Pres.


1265. Treatment Rates of Hepatitis C Virus (HCV) Infection Among Patients Co-Infected With HIV Over The Past Decade In An Urban Medical Center.  P. Suwandhi; K. Gopal; P. Benias; C. Wong; D. Meyer; H. C. Bodenheimer; A. D. Min View Pres.


1342. Pegylated interferon alpha plus ribavirin treatment of chronic hepatitis C in psoriatic patients..  K. Tomasiewicz; R. Modrzewska View Pres.


1276. Rivabirin upregulates autocrine interferon-beta and interferon-stimulated genes in the early phase of combination treatment with interferon-alpha.  Y. Tokumoto; Y. Hiasa; I. Konishi; T. Mashiba; B. Matsuura; K. Michitaka; M. Onji View Pres.


1329. Autonomic and sensory nerve function during 24 weeks of anti-HCV treatment. A follow-up study.  J. Osztovits; T. Horvath; J. Tax; E. Horváth; L. Csihi; T. Tóth; M. Abonyi; J. Fehér; M. Kollai; P. Kempler; F. Szalay View Pres.


1338. Management of Chronic Hepatitis C Patients with Schizophrenia: Should we treat?.  F. Barakat; E. Barber; D. L. Oliver; L. Petcharaporn; N. Karlen; L. M. Richards; E. Alpert; W. Perry; T. Hassanein View Pres.


1305. Three year follow-up of a multidisciplinary care and peer support model for the engagement of IDUs in care and treatment for HCV infection.  J. Grebely; E. Knight; T. Ngai; K. Genoway; F. Duncan; M. I. Viljoen; M. Storms; D. Elliott; J. D. Raffa; B. Conway View Pres.


1263. Prospective Analysis of Depression During Antiviral Treatment for Hepatitis C: Results of the VIRAHEP-C Study .  D. M. Evon; D. Ramcharran; S. H. Belle; N. Terrault; R. J. Fontana; M. W. Fried View Pres.


1246. Evaluation of Predictive Factors Associated with Sustained Viral Response to Peg-IFN plus Ribavirin Combination Therapy in Japanese Chronic Hepatitis C Patients.  H. Hashimoto; Y. Itoh; M. Minami; K. Yasui; H. Mitsuyoshi; K. Yamaguchi; M. Iwai; T. Okanoue; T. Yoshikawa View Pres.


1310. Efficacy Of Daily Dose Consensus Interferon Alfacon-1(CIFN) And Ribavirin In Previous Non Responders To Pegylated Interferon and Ribavirin In Patients With Advanced Fibrosis From Chronic Hepatitis C..  P. S. Mantry; M. Barnes View Pres.



1281. Frequent HCV RNA Testing Optimizes the Use of Peginterferon and Ribavirin for the Treatment of Chronic Hepatitis C Virus (HCV) .  M. L. Shiffman; S. B. Hubbard; A. G. Long; A. S. Price; C. Hofmann; P. G. Smith; J. Salvatori; D. L. Shelton; K. Williams; R. K. Sterling; V. A. Luketic; R. T. Stravitz; M. Fuchs; A. J. Sanyal View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1247. Evaluation of Early Null-response (eNR) as a Predictor of Nonresponse to PEG RBV in Patients with HCV.  N. Reau; A. DeVoss; C. Elsen; H. S. Te; R. Satoskar; S. R. Mohanty; K. G. Reddy; D. M. Jensen View Pres.


1299. High sustained virological response to peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience..  E. Veitsman; S. Edoardo; G. Hassoun; M. Lorber; K. Maor; R. Kramskay; S. Pollack; Y. Baruch View Pres.


1324. HCV genotypes regulate the occurrence of Rapid Virological Response (RVR) during antiviral therapy. .  M. Persico; M. Svelto; F. Moschella; E. Persico; V. La Mura; R. Torella View Pres.



1327. Iron reduction in chronic hepatitis C by repeated phlebotomy: A study using a less aggressive protocol.  I. Nagy; A. Palvolgyi; T. Korom View Pres.



1343. INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN HCV (+) NON RESPONDER CIRRHOTICS WITH HIGH LIVER CELL PROLIFERATION. .  M. Donato; E. Arosio; A. Aghemo; M. Rumi; G. Ronchi; M. Colombo View Pres.



1267. VALUE OF VON WILLEBRAND FACTOR ANTIGEN AS AN ON-TREATEMENT PREDICTOR OF RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS SUFFERING FROM CHRONIC HEPATITIS C.  S. Pramhas; M. Homoncik; P. Ferenci; A. Gangl; M. Peck-Radosavljevic View Pres
Blank
Avatar_m_tn
HCV infections .  . Övünç Kurdas; A. Tiftikci; B. Yasar; Z. Akkan Çetinkaya; M. Sezikli; F. Guzelbulut; A. T. Ince View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1248. Pretreatment assessment of PEG-interferon plus ribavirin anti-HCV therapy using viral genetic profiles, NS5A-ISDR and Core mutations..  N. Sakamoto; M. Nakagawa; C. Chen; Y. Itsui; M. Tasaka; N. Enomoto; M. Watanabe View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1302. Treatment compliance in patients taking RibaPak® or 200mg ribavirin: Preliminary analyses from the ADHERE registry.  V. K. Rustgi; I. Alam; B. Cecil; A. D. Tice ; T. Stainbrook; K. D. Ingram; K. David View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1270. Insulin-Resistance in Chronic Hepatitis C patients: New Predictor of Sustained Virological Response Independent of HCV Genotype and Liver Fibrosis Stage.  R. Moucari; M. Ripault; M. Martinot-Peignoux; H. Voitot; S. Maylin; A. Cardoso; T. Asselah; N. Boyer; M. Vidaud; D. Valla; P. Bedossa; P. Marcellin View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1269. Antiretrovirals reduce Ribavirin exposure in HIV-HCV coinfected patients.  J. Quioc; V. Jullien; V. Mallet; B. Nalpas; S. Pol View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1328. PPAR-alpha agonists as potential therapeutic option in HCV type1-infected patients.  V. Weich; N. Frost; B. Schlosser; F. Van Bömmel; U. Kintscher; T. Berg View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1300. AUTOIMMUNE THYROID DISEASE IN CHRONIC HEPATITIS C TREATED WITH PEG-IFN AND RIBAVIRIN: PREVALENCE, INCIDENCE AND INFLUENCE ON THERAPEUTIC OUTCOME IN 4498 NAIVES PATIENTS.  F. Morisco; M. Tartaglione; A. De Luna; P. Andreone; C. Coppola; N. Passariello; C. Carella; A. Scuteri; C. Iannacone; M. Sarracino; N. Caporaso View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1316. Can early transaminase (ALT) changes predict response to hepatitis C therapy?.  L. McLeman; L. Bailey; S. Burnett; P. Dundas; B. Vijayan; A. Fraser View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1256. Higher Response Rate from Peginterferon Alpha 2a Plus Ribavirin in Chronic Hepatitis C Patients with Hemophilia .  H. Sul; H. Kim; S. Chung; Y. Lee; S. Park; H. Lee; K. Yoo; S. Hwang; S. Chung; H. Oh; C. Choi; J. Kim; J. Do; J. Kim; S. Chang; S. Park View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1271. Insulin Resistant Chronic Hepatitis C (CHC): The Effect of Sustained Virological Response (SVR) on Insulin Resistance (IR) Status, Insulin Secretion, Lipid Profile and Adiponectin .  W. Soliman; M. Kuczynski; N. Perez-Gutierrez; I. Fantus; E. Heathcote View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1341. Heart Rate Variability parallels Changes in Psychiatric Scales in Interferon-Treated Patients With Chronic Hepatitis..  D. Pavanello; A. Dall'Arche; F. Campagna; R. Orsato; G. Ferri; L. Cavalletto; L. Chemello; G. I. Perini; A. Gatta; P. Amodio View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1230. Prognostic relevance and reliability of quantitative RT- PCR and the qualitative TMA assay .  B. Schlosser; M. Biermer; F. Van Bömmel; V. Weich; M. Chauvel; T. Berg View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1301. Relationship between insulin resistance (IR) and sustained virologic response (SVR) in the treatment of Hepatitis C virus (HCV) with interferon and ribavirin .  W. M. Cassidy; R. Horswell View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1257. Adherence and response rate to anti viral treatment do not seem to be affected by intravenous drug use in patients with chronic hepatitis C under substitution therapy.  S. Manolakopoulos; O. Anagnostou; M. Deutsch; E. Tiniakou; G. V. Papatheodoridis; E. K. Manesis; D. Tzourmakliotis; A. J. Archimandritis View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1243. Effect of Time to Response on Viral Breakthrough and Relapse Rates in Patients Infected With HCV Genotype 1 and Treated With Peginterferon Alfa-2a Plus Ribavirin .  M. L. Shiffman; F. M. Hamzeh; R. T. Chung View Pres.
Blank
Avatar_m_tn
therapy achieves a better rapid (RVR)and early (EVR) virological response in chronic


Mon, Nov 03
8:00 AM
No itinerary selected

1312. Serum Beta Lipoprotein Levels and Outcome of Hepatitis C Virus (HCV) Treatment in HIV Co-Infected Patients.  K. Gopal; P. Benias; P. Suwandhi; D. Meyer; H. C. Bodenheimer; A. D. Min View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1215. Prospective evaluation of liver stiffness dynamics during and after peginterferon alpha-ribavirin treatment in patients with chronic hepatitis C .  C. Hezode; L. Castera; I. Rosa; D. Roulot; V. Leroy; M. Bouvier-Alias; A. Mallat; F. Roudot-Thoraval; J. Pawlotsky View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1219. Engineering T Cells in Chronic HCV to Confer Novel Reactivity by Using HCV-Specific T Cell Receptor Gene Transfer .  L. Golden-Mason; Y. Zhang; N. Castelblanco; M. Nishimura; H. R. Rosen View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1217. Ribavirin Improves Second Phase Kinetics Through Enhanced Interferon Signaling in Genotype 1 HCV Infection.  J. J. Feld; M. S. Ko; K. Hara; G. A. Lutchman; Y. Rotman; T. Heller; M. G. Ghany; A. U. Neumann; T. Liang; J. H. Hoofnagle View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1317. Differences in Adherence to PEG-Interferon and Ribavirin Among Subgroups Perceived to be At-Risk for Non-Adherence.  V. Lo Re; V. Amorosa; A. Localio; R. M. O'Flynn; V. Teal; Z. Dorey-Stein; J. Kostman; R. Gross View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1315. Incidence and Predictors of hematological abnormalities during Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin..  A. Nachnani; W. K. Clarkston; L. M. Alba View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1216. Impact of Advanced Fibrosis and Cirrhosis on Sustained Virologic Response of HCV G1-Infected Patients: Results of The Canadian POWeR Program.  P. Marotta; C. Cooper; D. K. Wong; J. Farley; M. Elkashab; K. M. Peltekian; N. Abadir; R. N. Woolstencroft; R. J. Bailey View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1254. Natural Killer Cell Receptor (NKR) Expression on Natural Killer (NK) and Natural T (NT) Subsets Before and During anti-Viral Therapy – Implications for Treatment Outcome..  L. Golden-Mason; N. Castelblanco; H. R. Rosen View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1262. Hepatitis C Virus (HCV) Virologic Response Correlates With Therapy-Induced Cytopenias And Side Effects .  B. Pearlman; C. Ehleben; L. Lovett View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1264. Ribavirin Loading Before Starting Pegylated Interferon Therapy: Effect on RVR and EVR.  T. Hassanein; R. S. Pozza; K. Biando; F. Barakat; D. L. Oliver; L. Petcharaporn; N. Karlen; K. Hall; L. M. Richards; E. Alpert View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1330. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression.  L. Peyrin-Biroulet; J. Cadranel; J. Nousbaum; A. Oussalah; M. Seddik; V. Canva; P. Sogni; J. Guéant; M. Bigard; X. Roblin; J. Bronowicki View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1284. Central Hypothyroidism in patients with chronic hepatitis C.  D. E. Zantut-Wittmann ; M. P. Pavan; E. J. Pavin; F. L. Gonçales Junior View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1319. Treatment of Hepatitis C in Renal Failure Patients: A single center experience.  M. J. Rosati; B. Aqel; V. Balan; T. J. Byrne; E. J. Carey; D. D. Douglas; M. Harrison; R. L. Heilman; M. J. Mazur; K. L. Mekeel; A. Moss; D. C. Mulligan; K. S. Reddy; J. Rakela; H. E. Vargas View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1232. Re-infection following successful treatment for Hepatitis C virus Infection .  J. Farley; Y. Al-Khafaji View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1332. Portal regulatory T cells favor viral clearance during antiviral therapy against HCV..  J. Westin; M. Lagging; K. Hellstrand; S. W. Schalm; A. U. Neumann; S. Zeuzem; J. Pawlotsky; C. Ferrari; A. P. Dhillon View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1249. Effect of obesity on interferon stimulated genes expression in chronic HCV infection.  V. Aggarwal; C. S. Palmer; A. R. Lloyd; A. Zekry View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1233. Rapid virologic response is common in acute hepatitis C virus (HCV) infection regardless of genotype.  C. E. Birch; A. Y. Kim; L. L. Reyor; M. J. Bowen; E. H. Nagami; B. McGovern View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

1318. Standard or pegylated interferon with or without ribavirin treatment of hepatitis C after liver transplant: a meta-analysis..  G. K. Papazian View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

Session Title: HCV: Virology and Pathogenesis

Session Type: Poster Sessions


Location: West Hall (Moscone West Convention Center)

Start time: Sun, Nov 02 - 8:00 AM



1060. Immune senescence, independent of age, informs the clinical outcome of chronic Hepatitis C Virus (HCV) infection.  M. Hoare; W. Gelson; A. Das; J. M. Fletcher; S. Davies; M. D. Curran; S. L. Vowler; M. K. Maini; A. N. Akbar; G. J. Alexander View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1029. Chronic Hepatitis C and Occult Hepatitis C Virus Infection Are Characterized by Different Cytokine Expression Profiles in Circulating Immune Cells .  T. N. Pham ; S. E. Mercer (MRSA); T. I. Michalak View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

999. Predictive value of the phosphorylation of signal transducers and activators of transcription (STATs) in outcome of interferon therapy to chronic hepatitis C .  H. Miyaaki; K. Nakao; T. Ichikawa; M. Akiyama; E. Ozawa; S. Miuma; H. Shibata; T. Matsuzaki; T. Muraoka; S. Takeshita; K. Eguchi View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1068. INFECTION OF B CELLS WITH HEPATITIS C VIRUS IS ASSOCIATED WITH LYMPHOPROLIFERATIVE DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C.  M. Inokuchi; T. Ito; M. Uchikoshi; Y. Shimozuma; M. Imawari View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1016. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo..  P. Meuleman; J. Hesselgesser; M. Paulson; T. Vanwolleghem; I. Desombere; H. Reiser; G. Leroux-Roels View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1041. Impairment of Natural Killer Cell Activity of Lymphocytes in Chronic Hepatitis C Patients owing to Decreased Frequency of CD56dim NK Cells in Peripheral Blood.  I. Nakamura; K. Ochiai; M. Imawari View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1084. Microsomal triglyceride transfer protein (MTP) - 493 G/T polymorphism is associated with insulin resistance in chronic hepatitis C (CHC) genotype 1 infection .  É. F. Siqueira; C. P. Oliveira; M. Corrêa-Giannella; J. Stefano; A. Cavaleiro; M. Z. Fortes; M. C. Muniz; K. A. Silva; F. S. Silva; L. B. Pereira; F. J. Carrilho View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1017. Genetic variability of the carboxyl terminal region of protein E2 in both alcoholic and non-alcoholic patients suffering from chronic hepatitis C.  F. Simões; O. Simões; A. Martinho; L. Pais; A. Carvalho View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1062. Hepatitis C as a risk factor for primary renal cell carcinoma.  S. C. Gordon; D. Moonka; K. a. Brown; M. Y. Huang; S. E. Anteau; L. Lamerato View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1021. SERUM BLyS/BAFF LEVELS IN ACUTE HEPATITIS C PREDICT CLINICAL OUTCOME .  G. Tarantino; V. Di Marco; P. Almasio; F. Barbaria; R. Di Stefano; S. Petta; C. Tripodo; A. Craxì View Pres.


Blank
Avatar_m_tn

1004. Investigating the Vertical Transmission and Evolution of Hepatitis C Virus between Mother and Infant Pairs.  K. Goto; Y. Tanaka; T. Endo; K. Ito; A. A. Khan; M. Mizokami View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1056. Evidence for both direct and indirect regulation of HCV replication by TGF-β1.  W. Lin; R. Shao; L. F. Peng; S. Sabharwal; W. Chung; R. T. Chung View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1057. Natural history of HCV superinfection and reinfection .  P. A. White; J. Grebely; J. K. Flynn; G. Matthews; M. K. Renkin; B. Yeung; W. Rawlinson; J. Kaldor; M. Hellard; A. R. Lloyd; R. A. Ffrench; G. J. Dore View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1048. High Incidence of Hepatocellular Carcinoma associated with Hepatitis C Virus Genotype 3a in Pakistan.  A. A. Khan; Y. Tanaka; Z. Azam; Z. Abbas; F. Kurbanov; S. S. Hamid; S. Jafri; M. Mizokami View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1043. Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication .  M. Korenaga; K. Hino; S. Nishina; I. Sakaida View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1074. Promotion of Hepatic Stellate Cell Fibrogenesis and ICAM-1 Expression by Antigen Specific Immune Responses to HCV.  A. J. Fowell; L. B. Murphy; S. Johal; C. L. Brooks; A. E. Semper; W. M. Rosenberg View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1030. Differential Gene Expression of Patients with Hepatitis C Genotype 1 and Genotype 3 .  A. M. Wheeler; M. Stepanova; A. Baranova; A. Afendy; I. Bornman; K. Ankrah; R. D. Aquino; Z. M. Younossi View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1031. Differential Gene Expression between Caucasian and African American Patients with Chronic Hepatitis C (CH-C) .  A. Afendy; M. Stepanova; A. Baranova; N. Hossain; I. Younossi; A. M. Wheeler; Z. M. Younossi View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1032. Magnitude of HCV-specific CD8+ T cell responses and severity of hepatitis do not determine the outcome in acute HCV infection.  H. Doi; K. Hiroishi; J. Eguchi; T. Baba; S. Ishi; A. Hiraide; M. Sakaki; M. Imawari View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1037. EVALUATION OF SERUM B CELL ACTIVATING FACTOR (BAFF/BLyS) AS A IMMUNOLOGICAL MARKER OF LYMPHOPROLIFERATIVE DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C .  M. Uchikoshi; T. Ito; M. Inokuchi; Y. Shimozuma; M. Imawari View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1042. Iron overload causes hepatic steatosis through the endoplasmic reticulum stress in transgenic mice expressing the hepatitis C virus polyprotein.  S. Nishina; M. Korenaga; I. Hidaka; A. Sakai; A. Shinozaki; I. Sakaida; K. Hino View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1010. Alternation of regulatory T cells in patients with chronically hepatitis type C virus infection under pegylated interferon with ribavirin combination therapy.  M. Akiyama; Y. Motoyoshi; S. Takeshita; E. Ozawa; S. Miuma; H. Shibata; M. Fujimoto; H. Miyaaki; T. Ichikawa; K. Nakao; K. Eguchi View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1022. Severity of Liver Disease in Chronic Hepatitis C Patients: Latino versus Caucasian..  M. Y. Sheikh; M. H. Bashir; A. A. Afaq; H. Sadiq; J. Choudhury View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1026. The IFN antagonist SOCS3 Downregulates Hepatitis C Virus Replication in Cell Culture .  R. Shao; W. Lin; L. F. Peng; S. Sabharwal; W. Chung; R. T. Chung View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1075. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation.  Y. Eguchi; T. Mizuta; E. Ishibashi; T. Eguchi; A. Matsunobu; N. Oza; S. Nakashita; Y. Kitajima; H. Takahashi; Y. Kawaguchi; R. Iwakiri; I. Ozaki; N. Ono; K. Fujimoto View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1007. Binding dynamics of Hepatitis C Virus’ Nonstructural proteins to Cell and Model Membranes.  N. Cho; C. W. Frank; J. S. Glenn View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1012. Long term ApoB-dependent HCV secretion is blocked by the grapefruit flavonoid naringenin.  Y. Nahmias; J. Goldwasser ; M. L. Yarmush; R. T. Chung View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1069. Lymphotropic HCV strain can replicate in primary naïve CD4+ cells and suppress the development and proliferation activity..  Y. Kondo; Y. Ueno; K. Kobayashi; E. Kakazu; K. Machida; S. Kon; M. Shiina; K. Tamai; J. Inoue; M. Ninomiya; Y. Wakui; K. Fukushima; T. Kogure; M. M. Lai; T. Shimosegawa View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1065. Inactivation of Cardif, an Essential Adaptor Protein in the RIG-I Antiviral Pathway, in Patients with Hepatitis C.  P. Bellecave; M. Sarasin-Filipowicz; O. Donze; J. Gouttenoire; E. Meylan; J. Tschopp; C. Sarrazin; T. Berg; M. H. Heim; D. Moradpour View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1002. HBV-HCV Coinfection: Insights from a Novel Model System.  P. Bellecave; J. Gouttenoire; M. Gajer; V. Brass; G. Koutsoudakis; H. E. ****; M. Nassal; R. Bartenschlager; D. Moradpour View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1085. Selective induction of HCV core-specific adaptive Foxp3+CD25+CD4+ regulatory T cells in chronic hepatitis C .  B. Langhans; I. Braunschweiger; S. Arndt; W. Schulte; J. Satoguina; N. Vidovic; A. Hoerauf; J. Oldenburg; T. Sauerbruch; U. Spengler View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1044. Serum levels of the major type III interferon IL-29 are differentially affected in acute and chronic hepatitis C .  B. Langhans; I. Braunschweiger; S. Arndt; M. Michalk; B. Kupfer; G. Gornik; N. Vidovic; L. Leifeld; J. Oldenburg; T. Sauerbruch; U. Spengler View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1061. Viral fitness cost and T cell cross-recognition limit viral escape within a protective HLA-B27 restricted hepatitis C virus specific CD8+ T cell epitope.  C. Neumann-Haefelin; E. Dazert; S. Bressanelli; K. Fitzmaurice; J. Timm; S. McKiernan; D. Kelleher; P. Klenerman; H. E. ****; R. Bartenschlager; R. Thimme View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1018. Anisoosmolarity alters HCV replication in the subgenomic hepatitis C virus replicon system.  H. Fey; B. Sitek; K. Stühler; H. E. Meyer; D. Haussinger; A. Erhardt View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1009. Interruption of hepatitis C virus particle formation by an intracelllular antibody targeting the viral core protein.  R. Machida; S. Tong; T. Heintges; T. Wakita; J. R. Wands; J. Li View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

995. Hepatitis C virus non-structural 4B protein-protein interaction depends on an intact basic leucine zipper localized within the aminoterminal part.  M. W. Welker; C. Welsch; A. K. Meyer; G. Plotz; N. Forestier; B. Kronenberger; T. Lengauer; A. Piiper; S. Zeuzem; C. Sarrazin View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1023. Diversity of amino acid sequences within the HCV E2 protein in PBMC and serum.  M. W. Welker; D. Ochs; C. Welsch; E. Herrmann; R. W. Hartmann; S. Zeuzem; C. Sarrazin; B. Kronenberger View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1054. Hepatic Apoptotic Markers are Associated with Histology but may not Predict the Response to Therapy in Chronic Hepatitis C.  R. Ozaras; V. Tahan; G. Ozbay; C. Celikel; K. Midilli; A. Kaygusuz; N. Arican; N. Yenice; B. Ceylan; M. Fincanci; Z. Gucin; R. Ozturk; F. Tabak; N. Tozun; H. Senturk; A. Mert View Pres.

Blank
Avatar_m_tn

Mon, Nov 03
8:00 AM
No itinerary selected

1320. Doubling of standard peginterferons (pegifn) doses only in the first month of Sun, Nov 02
8:00 AM
No itinerary selected


Sun, Nov 02
8:00 AM
No itinerary selected

1001. A high throughput system for phenotypic analysis of NS3 sequences.  J. Hong; X. Qin; S. Lim; L. M. Blatt; S. Seiwert View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1024. Identification of cellular microRNAs that block IFN-alpha action against hepatitis C virus IRES mediated translation .  N. S. Dally; T. M. Gage; S. Hazari; S. Haque; S. Dash View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1033. Decreased Active Glucagon-like Peptide-1 and Increased Dipeptidyl Peptidase-4 Expressions in Patients with HCV-related Insulin Resistance.  M. Itou; T. Kawaguchi; E. Taniguchi; T. Oriishi; S. Sumie; K. Mitsuyama; O. Tsuruta; T. Ueno; M. Sata View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1083. Up-regulated cholesterol synthesis in an HCV-infected liver: The impact on Interferon treatment via cholesterol~geranylgeranyl diphosphate~PIAS/PP2A pathways.  M. Nakamuta; M. Yada; R. Yada; Y. Amagase; N. Yamamoto; R. Takemoto; T. Yoshimoto; T. Miyahara; K. Fukuizumi; N. Harada; S. Morizono; S. Maekawa; N. Enomoto; A. Taketomi; Y. Maehara; M. Enjoji View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1071. Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperone, prohibitin, in cells expressing hepatitis C virus core protein.  K. Koike; T. Tsutsumi; M. Matsuda; H. Aizaki; K. Moriya; H. Miyoshi; H. Fujie; Y. Shintani; H. Yotsuyanagi; T. Miyamura; T. Suzuki View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1045. Steatosis and intrahepatic expression levels of genes regulating lipid metabolism in Japanese patients with chronic hepatitis C.  K. Yasui; Y. Harano; H. Mitsuyoshi; K. Tsuji; M. Minami; Y. Itoh; T. Okanoue; T. Yoshikawa View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1003. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles.  T. Suzuki View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1014. Zinc dynamism in HCV replicon. .  H. Takagi; D. Takizawa; K. Yuasa; T. Ichikawa; K. Sato; S. Kakizaki; M. Mori; M. Ikeda; N. Kato View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1070. Natural killer cell phenotypes in chronic hepatitis C infection: correlation with genetics and the outcome of treatment..  R. J. Harrison; L. S. Brackenbury; A. Little; S. I. Khakoo View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1034. The balance between CD56+bright and CD56+dim natural killer cell subsets in the liver of patients with recurrent hepatitis C after liver transplantation.  S. Yamagiwa; H. Kamimura; A. Tsuchiya; M. Takamura; Y. Matsuda; Y. Sato; T. Ichida; Y. Aoyagi View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1005. Analysis of peripheral blood CD4 T-cell responses in patients with chronic HCV infection according to CD154 expression .  E. Schott; J. F. Moeller; B. Wiedenmann; T. Berg View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1066. Is HOMA-IR the best marker of insulin resistance in chronic hepatitis due to HCV infection?.  R. Narita; M. Hiura; S. Abe; Y. Kihara; A. Tabaru; M. Otsuki View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1087. Hepatitis C virus proteins can modulate microRNA expression and chemotherapeutic responses in Hepatocellular Carcinoma (HCC).  C. Braconi; F. Meng; N. Huang; T. Suzuki; C. Taccioli; C. Croce; T. Patel View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1036. Ductular reaction is driven by insulin resistance and undergo epithelial-mesenchymal transition in chronic hepatitis C..  G. Svegliati-Baroni; G. Faraci; S. Saccomanno; L. Fabris; M. Lo Cascio; M. Cadamuro; M. Strazzabosco; E. Bugianesi; A. Benedetti; G. Marchesini View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

997. Infectious HCV Produces a Family of Mini-core Proteins.  F. J. Eng; A. L. Klepper; J. L. Walewski; L. K. McMullan; M. J. Evans; C. M. Rice; S. M. Desai; A. D. Branch View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1067. The hepatitis C virus non-structural 3/4A protease cleaves the T-cell protein tyrosine phosphatase thereby interfering with EGF-induced signal-transduction .  E. D. Brenndörfer; J. Karthe; M. Sallberg; P. Cebula; A. Erhardt; D. Häussinger; J. G. Bode View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected


Blank
Avatar_m_tn
1086. Dysregulation of killer inhibitory and activating receptor expression on NK and cytotoxic T cells in chronic HCV hepatitis .  G. Par; L. Szereday; A. Vincze; A. Par View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1038. CD4+CD25+FoxP3+ REGULATORY T CELLS IN CHRONIC HEPATITIS C .  M. Raptopoulou-Gigi; A. Bellou; A. Sarantopoulos; E. Gigi; E. Sinakos; E. Orfanou; E. Vrettou; P. Boura View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1072. Antigen-Specific Lymphocyte Proliferation Decreases Over Time in Advanced Chronic Hepatitis C and Its Loss is Associated with the Presence of Cirrhosis.  C. Morishima; A. M. Di Bisceglie; M. J. Koziel; A. L. Rothman; H. L. Bonkovsky; W. M. Lee; K. Lindsay; E. C. Wright View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1013. Hepatitis C virus translation and replication is highly dependent on translation initiation factors .  T. Shirasaki; M. Honda; T. Shimakami; H. Okada; Y. Sakai; S. Kaneko View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1077. Dynamic changes of regulatory T cell subsets in patients with chronic HCV infection in relation to the degree of liver inflammation.  I. Itose; T. Kanto; S. Takebe; K. Higashitani; N. Kakita; M. Miyazaki; H. Miyatake; M. Sakakibara; N. Hiramatsu; T. Takehara; A. Kasahara; N. Hayashi View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1006. The interferon stimulated gene 15 is an important proviral factor for the hepatitis C virus .  R. Broering; M. Trippler; G. Gerken; J. F. Schlaak View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1088. IL-7 as a booster of Th2-differentiation by modulating myeloid dendritic cells in chronic hepatitis C virus infection.  S. Takebe; T. Kanto; H. Miyatake; K. Higashitani; N. Kakita; M. Miyazaki; I. Itose; M. Sakakibara; N. Hiramatsu; T. Takehara; A. Kasahara; N. Hayashi View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1025. The NTPase/helicase Domain of Hepatitis C Virus Nonstructural Protein 3 (NS3) inhibits PKC Family Kinases in vitro and induces Phenotypic Alterations in NIH 3T3 Cells.  P. Hartjen; P. Borowski View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

996. HCV replication in engineered HepG2 and HepaRG cells that have impaired innate imune responses .  D. Durantel; J. Lucifora; C. Alotte; M. Maire; F. Cosset; B. Bartosch; F. Zoulim View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1052. Hepatitis C Virus Core Protein Promotes the Development of Hepatocelular Carcinoma through the Inhibition of Apoptosis in Transgenic Mice .  k. zhang; F. Imazeki; K. Fukai; M. Arai; O. Yokosuka View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1079. Distribution of HLA-E allelic variants in HCV-infection.  D. Schulte; B. Krämer; C. Koerner; H. Nischalke; T. Sauerbruch; J. Nattermann; U. Spengler View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1051. Altered distribution of T cell subsets in patients with different manifestations of HCV-related chronic liver disease..  S. Ferri; M. Bassi; C. De Molo; R. Menichella; R. Cicola; A. Dall'Aglio; A. Granito; G. Pappas; C. Quarneti; P. Muratori; M. Lenzi; F. B. Bianchi; L. Muratori View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1008. TETRASPANIN-ENRICHED MICRODOMAINS INVOLVEMENT IN HEPATITIS C VIRUS INFECTION: ROLE OF CD151..  P. Sanz-Cameno; S. Martin-Vilchez; Y. Rodriguez-Muñoz.; M. J. Borque; M. Trapero-Marugán; L. García-Buey; M. Lopez-Cabrera.; R. Moreno-Otero View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1076. Hepatitis C virus coinfection enhances apoptosis of CD4+ T cells in patients with HIV infection.  C. Koerner; B. Krämer; D. Schulte; S. Mauss; J. Nattermann; J. Rockstroh; T. Sauerbruch; U. Spengler View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

998. HCV genomic RNA dimerizes via a kissing complex intermediate in the 3’-UTR.  S. Shetty; M. Mihailescu View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1064. Gene expression profiling in liver of chronic hepatitis C patients undergoing interferon therapy reveals the signaling pathway of interferon resistance .  M. Honda; M. Tateno; M. Nakamura; A. Sakai; S. Kaneko View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1078. Humoral neutralizing response to HCV during HIV coinfection and liver transplantation.  G. Maurin; A. Roque-Afonso; P. Vaghefi; M. Gigou; J. Duclos-Vallee; F. Cosset; D. Samuel; D. Lavillette; C. Feray View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1019. Hepatitis C Viral Genotype Age is a Predictor of the Clinical Response to Interferon Therapy .  P. S. Pang; P. J. Planet; J. S. Glenn View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1046. Serum hepcidin levels are related to viral load and to histological severity of liver lessions in chronic hepatitis C.  E. Tsochatzis; G. V. Papatheodoridis; V. Koliaraki; E. K. Manesis; A. Mamalaki; A. J. Archimandritis View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1015. Hepatitis C virus (HCV) core proteins of different lengths localize in distinct subcellular compartments suggesting nuclear-cytoplasmic shuttling.  M. E. Burlone; R. Minisini; A. Cerutti; P. Maillard; M. Pirisi; A. Budkowska View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1047. Hepatitis C Virus (HCV) Specific CD4+ and CD8+ T-Cell Responses in Patients with Chronic Hepatitis C and the Impact of HIV Coinfection.  N. I. Rallón; M. López; V. Soriano; J. García-Samaniego; M. Romero; P. Labarga; J. González-Lahoz; J. M. Benito View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1063. Functional compartmentalization of hepatitis C virus NS5A quasispecies variants in the liver of patients with chronic hepatitis C and hepatocellular carcinoma.  H. Lerat; S. Carmouse; J. Zucman-Rossi; P. Bioulac-Sage; J. Pawlotsky View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1039. Adiponectin Inhibits Steatotic Upregulation of CD95/Fas and Apoptosis by Hepatocytes.  I. Wedemeyer; L. Bechmann; M. Odenthal; C. Jochum; G. Marquitan; U. Drebber; G. Gerken; H. Dienes; A. Canbay View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1049. Increased Hepatic Progenitor Cells and Ductular Reaction in Pre- and Post-Perfusion Liver Biopsies Occurring in Older Donor Livers .  S. N. Sclair; T. D. Schiano; H. Wu; M. Fiel View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1011. Long term follow up of patients previously treated with telaprevir .  N. Forestier; S. Susser; M. W. Welker; U. Karey; S. Zeuzem; C. Sarrazin View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1028. Lipogenesis activation does not depend on endoplasmic reticulum stress in a mouse model of hepatocellular steatosis induced by hepatitis C virus .  H. Lerat; H. Kammoun; I. Hainault; E. Merour; C. Callens; S. M. Lemon; F. Foufelle; J. Pawlotsky View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1020. MODULATION OF OXIDATIVE STRESS IN THE NEGATIVE REGULATION OF HCV INDUCED BY ASA..  A. G. Rivas-Estilla; O. Bryan-Marrugo; K. d. Trujillo-Murillo; D. Perez-Ivabe; P. Cordero perez; R. Ortiz-Lopez View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1059. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of T lymphocytes with regulatory phenotype and function .  A. Dolganiuc; G. Szabo View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1050. Cytokine and chemokine expression patterns connect various host and viral characteristics with clinical outcome in chronic HCV infection.  A. Katsounas; R. A. Lempicki; S. Kottilil; M. Trippler; S. Bein; G. Gerken; J. F. Schlaak View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected
Blank
Avatar_m_tn


1082. Histone deacetylase inhibition restores hepcidin expression in HCV replicon cells.  K. Miura; K. Taura; Y. Kodama; D. A. Brenner View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1080. Slow liver fibrosis progression in chronic HCV infection is associated with greater suppression of peripheral and intrahepatic HCV-specific T cell responses.  N. Alatrakchi; I. Nasser; M. Kress; Q. He; M. A. Exley; N. H. Afdhal; M. J. Koziel View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1055. Amino acid substitutions in the hepatitis C virus core region induces glucose intolerance in patients with infected-HCV .  M. Korenaga; K. Hino; I. Sakaida View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1035. Hepcidin expression is decreased in hepatitis C virus replicons and permissive hepatoma cell lines.  A. T. Wilson; M. Mathahs; K. A. Broadhurst; Z. Zhu; K. Brown; B. A. Luxon; W. N. Schmidt View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

994. Dynamical Archiving - a Novel Mechanism for Post-Treatment Long Term Persistence of Resistant HCV Strains to Direct Anti-viral Drugs.  A. U. Neumann View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1053. Immune restoration and HCV quasispecies evolution in HIV coinfected patients.  P. Vaghefi; G. Maurin; D. Lavillette; C. Feray; E. Dussaix; A. Roque-Afonso View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1081. Effect of Steatosis on the intrahepatic cytokine/chemokine responses in chronic HCV.  C. S. Palmer; N. Nguyen; A. R. Lloyd; A. Zekry View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1040. A Novel Immune Measure Distinguishes HCV from Alcoholic Cirrhosis .  M. Lehil; J. C. Ryan; M. S. Kim ; S. George; E. Sheen ; A. E. Kennedy; A. Monto View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1058. TLR4 signaling induces progenitor/stem marker Nanog and liver tumor development by hepatitis c virus NS5A and alcohol/diabetes-mediated endotoxin.  K. Machida; H. Tsukamoto; M. Liu; L. Duan; R. Fang; S. Hess; R. Deshaies; S. Govindarajan; R. Ray; M. M. Lai View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1000. Nitazoxanide Inhibits Hepatitis C Virus Replication In Vitro.  T. Schaninger; J. Hong; G. G. Luo View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

993. Much of the HCV RNA in Infected Human Cells Is in Double-stranded RNA (dsRNA) Replication Complexes and Is Invisible to Standard Detection Methods.  A. L. Klepper; J. Garber; J. L. Walewski; J. A. Gutierrez; T. D. Schiano; A. D. Branch View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1027. Regulatory T cells in early hepatitis C infection.  J. H. Wang; X. Ke; M. J. Pianko; A. Herskovic; B. Boodram; R. Hershow; S. J. Cotler; M. O’Gorman View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

1073. Ethanol and acetaldehyde enhance hepatitis C virus replication in human hepatoma cells supporting infectious virus production.  S. Seronello; C. Ito; T. Wakita; J. Choi View Pres.


Sun, Nov 02
8:00 AM
No itinerary selected

Session Title: IASL Parallel I: Viral Hepatitis

Session Type: Parallel Sessions


Moderator: Ding-Shinn Chen
Moderator: E. Jenny Heathcote

Location: Yerba Buena Salon 7 (Marriott)

Start time: Sun, Nov 02 - 2:00 PM



27. Prospective evaluation by paired liver biopsy of HCV disease progression in patients (pts) co-infected with HIV. .  R. K. Sterling; P. G. Smith; J. Wegelin; M. L. Shiffman; R. T. Stravitz; V. A. Luketic; M. Fuchs; A. J. Sanyal View Pres.


Sun, Nov 02
2:30 PM
No itinerary selected

26. A Randomized Trial of 24- versus 48-week Peginterferon Alfa-2a Plus Ribavirin for Treatment-Naïve Taiwanese Patients with Hepatitis C Virus Genotype 1 Infection.  C. Liu; C. Liu; C. Lin; C. Liang; S. Hsu; S. Yang; C. Hsu; T. Tseng; C. Wang; M. Lai; J. Chen; P. Chen; D. Chen; J. Kao View Pres.


Sun, Nov 02
2:15 PM
No itinerary selected

29. Acute /recent HCV infection. Clinical Laboratory variants. Host andViral characteristics..  T. Tsertsvadze; L. Sharvadze; M. Karchava; A. Abutidze; E. Dolmazashvili View Pres.


Sun, Nov 02
3:00 PM
No itinerary selected

25. long-term outcome of hepatitis c virus carrier with persistent normal alanine aminotransferase level, a prospective cohort study.  J. Takada; T. Nakazawa; Y. Okuwaki; M. Watanabe; H. Hidaka; A. Shibuya; K. Saigenji View Pres.


Sun, Nov 02
2:00 PM
No itinerary selected

30. Spontaneous viral clearance in HCV seroconverters .  C. van den Berg; J. Schinkel; T. J. van de Laar; R. Molenkamp; D. van Baarle; R. Coutinho; M. Prins View Pres.


Sun, Nov 02
3:15 PM
No itinerary selected

Session Title: IASL Parallel III: Hepatocellular Carcinoma

Session Type: Parallel Sessions


Moderator: Federico Guillermo Villamil
Moderator: Jordi Bruix

Location: Yerba Buena Salon 5/6 (Marriott)

Start time: Sun, Nov 02 - 4:00 PM



78. Hepatocellular Carcinoma associated to chronic Hepatitis Delta.  R. Romeo; A. Russo; A. Sangiovanni; E. Del Ninno; M. Rumi; M. Colombo View Pres.


Sun, Nov 02
4:00 PM
No itinerary selected

80. INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN HCV (+) NON RESPONDER CIRRHOTICS WITH HIGH LIVER CELL PROLIFERATION. .  M. Donato; E. Arosio; A. Aghemo; M. Rumi; G. Ronchi; M. Colombo View Pres.


Sun, Nov 02
4:30 PM
No itinerary selected

Blank
Avatar_m_tn
.
79. HCV in Liver Cancer Patients Has Characteristic Mutations in the Core Gene.  S. Fishman; S. Factor; C. Balestrieri; S. M. Desai; A. M. Di Bisceglie; G. Benson; A. D. Branch View Pres.


Sun, Nov 02
4:15 PM
No itinerary selected

Session Title: IASL Parallel IV: Hepatitis/Cholestasis

Session Type: Parallel Sessions


Moderator: George K Lau
Moderator: Jean-Michel Pawlotsky

Location: Yerba Buena Salon 7 (Marriott)

Start time: Sun, Nov 02 - 4:00 PM



87. Evaluation of a 4 Week Lead-In Phase with Nitazoxanide (NTZ) Prior To Peginterferon (PegIFN) Plus NTZ for Treatment of Chronic Hepatitis C: Final Report.  J. Rossignol; A. Elfert; E. B. Keeffe View Pres.


Sun, Nov 02
4:15 PM
No itinerary selected

88. A clinicopathological comparison of HIV/Hepatitis B co-infection and Hepatitis B mono-infection in Cape Town, South Africa.  M. W. Sonderup; H. Wainwright; H. N. Hairwadzi; C. W. Spearman View Pres.


Sun, Nov 02
4:30 PM
No itinerary selected

90. Rapid virologic response is common in acute hepatitis C virus (HCV) infection regardless of genotype.  C. E. Birch; A. Y. Kim; L. L. Reyor; M. J. Bowen; E. H. Nagami; B. McGovern View Pres.


Sun, Nov 02
5:00 PM
No itinerary selected

Session Title: IASL Plenary 1

Session Type: Plenary Sessions


Moderator: Thomas D Boyer
Moderator: Wolfgang H Caselmann

Location: Yerba Buena Salon 7 (Marriott)

Start time: Sun, Nov 02 - 9:00 AM



12. PREVALENCE AND CAUSES OF DISCORDANCE BETWEEN FIBROSCAN AND FIBROTEST FOR FIRST-LINE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS C (CHC): A PROSPECTIVE ANALYSIS OVER 4 YEARS IN 3148 PATIENTS .  L. Castera; M. Haaser; B. Le Bail; J. Foucher; P. Bernard; W. Merrouche; V. de Ledinghen ; P. Couzigou View Pres.


Sun, Nov 02
10:15 AM
No itinerary selected

10. HBV superinfection in HCV chronic carriers is associated with severe acute hepatitis and clearance of HCV chronic replication.  N. Coppola; M. Pisaturo; A. Masiello; G. Tonziello; C. Sagnelli; V. Messina; P. Filippini; E. Sagnelli View Pres.


Sun, Nov 02
9:45 AM
No itinerary selected

11. Error Factors for Transient Elastography in Chronic Hepatitis C.  V. Calvaruso; C. Cammà; V. Di Marco; S. Maimone; F. Bronte; M. Enea; M. Pleguezuelo; E. Xirouchakis; M. Misseri; P. Manousou; G. M. Dusheiko; A. K. Burroughs; A. Craxì View Pres.


Sun, Nov 02
10:00 AM
No itinerary selected

Session Title: IASL Plenary 2

Session Type: Plenary Sessions


Moderator: Gamal Esmat
Moderator: Didier Lebrec

Location: Yerba Buena Salon 7 (Marriott)

Start time: Sun, Nov 02 - 11:15 AM



18. Proteomic Profiling of Serum using SELDI-TOF MS in Hepatitis C (HCV) infected individuals on treatment with Pegylated Interferon-α and Ribavirin.  E. J. Devitt; K. A. Power; J. A. Browne; W. M. Gallagher; J. P. Crowe View Pres.


Sun, Nov 02
12:30 PM
No itinerary selected

14. Effect of Rituximab on advanced liver disease in patients with HCV-related mixed cryoglobulinemia.  A. Petrarca; L. Rigacci; U. Arena; F. Vizzutti; C. Giannini; P. Montalto; A. Bosi; S. Colagrande; P. Romagnoli; G. Laffi; A. Zignego View Pres.


Sun, Nov 02
11:30 AM
No itinerary selected

17. Characterization of a new amino acid substitution (V36C) associated with telaprevir (VX-950) resistance in a patient treated with telaprevir, peginterferon alpha-2a and ribavirin.  L. Barbotte; A. Ahmed-Belkacem; S. Chevaliez; A. Soulier; C. Hezode; J. Pawlotsky View Pres.


Sun, Nov 02
12:15 PM
No itinerary selected

Session Title: IASL Posters

Session Type: Poster Sessions


Location: Default

Start time: Sat, Nov 01 - 2:00 PM



509. PK/PD Modeling of Continuous Interferon Therapy for HCV.  C. Hamlen; E. A. Grovender; C. Wieneke; M. F. Wolf; Z. Wang; A. Vetter; R. M. Scherer; B. Van Antwerp View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

495. Disease severity undermines the role of serum retinol-binding protein 4 in the identification of insulin resistance in chronic hepatitis C .  J. Huang; M. Yu; S. Shin; C. Dai; L. Lee; W. Chang; W. Chuang View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

506. Use of alpha-fetoprotein and platelet count for prediction of hepatocarcinogenesis in patients with chronic hepatitis C virus infection.  M. Tateyama; H. Yatsuhashi; N. Taura; S. Nagaoka; S. Abiru; K. Yano; A. Komori; M. Ito; H. Ishibashi View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

508. Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment.  N. Rizk; M. F. Derbala; S. R. Al-Kaabi; A. M. Amer; F. Shebl; A. D. Al-Marri; I. I. Aigha; D. M. Alyaesi; H. M. Mohammed; H. M. Aman; N. M. Basem View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

512. Peginterferon Alfa-2a monotherapy could be a treatment option for Chronic Hepatitis C in Patients Infected with HCV Genotype 2.  K. Takaguchi; T. Nagano; M. Wato; N. Baba; T. Seno; T. Inaba; S. Watanabe; K. Kawai View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

519. Association of plasma branched-chain amino acids with fatigue in patients with chronic liver diseases in Japan.  A. Tanaka; S. Nezu; K. Kikuchi; S. Uegaki; A. Shibuya; N. Hanawa; M. Aiso; H. Miyakawa; S. Takahashi; H. Takikawa View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

504. The Illness Intrusiveness of a Hepatitis C Diagnosis.  M. B. Murphy View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

510. Consistent Results For Antiviral Activity And Safety Of Sustained Release Interferon-Alpha-2b (IFN-Alpha-2b XL) Compared To Marketed IFN-Alpha-2b And Its Pegylated Form (Peg-IFN-Alpha-2b) In Two Phase I Trials In Hepatitis C (HCV) Patients.  C. Trepo; R. Rouzier; C. Raffanel; M. Maynard-Muet; H. Belhadj-Tahar; M. Bourliere; Y. Donazzolo; P. Pradat; P. Berthillon; M. Guest; J. Grassot; R. Meyrueix; F. Nicolas; R. Kravtzoff View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

511. Prediction of sustained virological response by combining data mining analysis and stepwise regression in HCV genotype 1 patients treated with pegylated interferon alpha-2b and ribavirin.  H. Yatsuhashi; M. Kato; M. Nakamuta; N. Masaki; K. Hiroshi; T. Komeda; T. Satoh; T. Hijioka; T. Komatsu; M. Yagura; S. Hayashi; H. Ota; T. Muro; M. Kobayashi; M. Koga; K. Yano; N. Taura; A. Komori; S. Abiru; M. Nakamura; H. Fujioka; K. Migita; H. Ishibashi View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

520. Sustained virological response (SVR) to pegylated interferon and ribavirin has no effect on neurocognition and cerebral metabolite levels in patients with chronic hepatitis C..  V. Pattullo; M. McAndrews; M. Mrkonjic; A. Damyanovich; E. Heathcote View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

498. HCV genotypes in southern Italy: any evidence for a shift?.  P. Pizzillo; P. L. Almasio; D. Ferraro; N. Urone; R. Di Stefano; A. Craxì View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

516. Characteristics of hepatitis delta in northern California.  D. Yi; S. F. Baqai; R. G. Gish View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

496. THE INFLUENCE OF HLA IN THE CLINICAL OUTCOME OF PATIENTS WITH CHRONIC HEPATITIS C.  L. F. Cangussu; M. Gerbase-DeLima; S. A. Mingoti; E. F. Campos; G. F. Rampim; O. Martins Filho; R. Teixeira View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

505. High RNA HCV as Associated Factor to Hyperglycemia in Hepatitis C Chronic Patients.  J. A. Mata-Marin View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

500. Can simple biomarkers predict progression of fibrosis in HCV infection ?.  R. R. Mummadi; J. R. Petersen; N. Snyder View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected
Blank
Avatar_m_tn


501. FIBROTEST OR FIBROSCAN FOR EVALUATION OF LIVER FIBROSIS IN HEMOPHILIA PATIENTS INFECTED WITH HEPATITIS C.  Y. Maor; P. Halfon; D. Bashari; G. Penaranda; G. Morali ; R. Klar; S. Bar-Meir; U. Martinowitz; R. Oren View Pres.


502. LIVER HISTOLOGY IN HIV/HCV COINFECTED PATIENTS WITH PERSISTENTLY NORMAL SERUM AMINOTRANSFERASES.  C. Sagnelli; C. Uberti-Foppa; L. Galli; G. Pasquale; N. Coppola; A. Masiello; L. Albarello; C. Doglioni; A. Lazzarin; E. Sagnelli View Pres.



513. Addition of adefovir dipivoxil to lamivudine in chronic hepatitis B patients with YMDD mutation. The long-term follow-up results: .  C. P. Eyigun; H. C. Gul; O. Coskun; E. Gunal; H. Erdem; I. Y. Avci; L. Gorenek; B. A. Besirbellioglu; A. Kubar View Pres.



507. Title: Prevalence of Chronic Viral Hepatitis in South Asians Immigrants – People from Pakistan have high rates of infection with hepatitis C and high rates of hepatitis C induced cirrhosis in middle age. .  G. Uddin; G. R. Foster View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

514. Demonstration of YMDD Mutation in Liver Tissues of 14 Chronic Hepatitis B Patients under Lamivudine Therapy.  C. P. Eyigun; E. Gunal; A. Kubar; H. C. Gul; O. Coskun; I. Y. Avci; H. Erdem; L. Gorenek; B. A. Besirbellioglu View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

515. Analyzing HBV-DNA in Liver Tissue for Investigation of Unexplained ALT Elevation in HBsAg Positive Patients with Undetectable Serum HBV-DNA .  C. P. Eyigun; O. Coskun; H. C. Gul; E. Gunal; A. Kubar; I. Y. Avci; H. Erdem; B. A. Besirbellioglu; L. Gorenek View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

518. Hepatitis B Genotype Distribution and High Frequency of Lamivudine Resistance Mutations in Brazilian HIV/Hepatitis B Virus Co-infected Patients.  M. Mendes-Correa; J. R. Pinho; O. M. Leite; L. G. Martins ; A. G. Leite; M. H. Silva; R. Sitnik; D. E. Uip View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

497. Hepatitis C virus viremia and low platelet count: a community-based study in a hepatitis B and C endemic are in Taiwan.  C. Dai; W. Chuang; J. Huang; M. Hsieh; W. Chang; M. Yu View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

499. Pre-treatment genetic variability of NS5A region on patients infected with HCV genotype 1.  A. G. Jardim; L. T. Yamasaki; A. L. Queiróz; C. Bittar; J. R. Pinho; C. A. Carareto; P. Rahal; I. V. Mello View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

503. An On-going Outbreak of Acute HCV in HIV-infected Men in New York City: Rates of Spontaneous Clearance and Treatment Responses .  A. J. Uriel; D. S. Fierer; D. C. Carriero; A. L. Klepper; S. Fishman; S. Factor; M. Fiel; S. N. Thung; M. P. Mullen; D. T. Dieterich; A. D. Branch View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

517. Epidemiological, clinical, and virological features of 95 acute hepatitis A over a 33-month period in south-eastern France.  A. Motte; P. Borentain; P. Minodier; C. Dhiver; D. Botta-Fridlund; M. Henry; C. Tamalet; R. Gérolami; P. Colson View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

521. Title : Hepatitis c among HEAVY ALCOHOL CONSUMERS : Does it requires treatment ?.  M. Pascal; M. Marie; S. Maud; G. Michel View Pres.


Sat, Nov 01
2:00 PM
No itinerary selected

Session Title: Late-breaking Abstracts

Session Type: Late Breaking Abstracts


Moderator: Jacquelyn J Maher
Moderator: Anna Mae Diehl

Location: General Session Room (Moscone West Convention Center)

Start time: Mon, Nov 03 - 3:00 PM



LB6. Metformin with Peginterferon Alfa-2a and Ribavirin in the Treatment of Naïve Genotype 1 Chronic Hepatitis C Patients with Insulin Resistance (TRIC-1): Final Results of a Randomized and Double-Blinded Trial..  M. Romero-Gomez; M. Diago; R. J. Andrade; J. Calleja; J. Salmeron; C. M. Fernández-Rodriguez; R. Solà; J. M. Herrerías; I. Carmona; J. García-Samaniego; R. Moreno-Otero; R. Morillas; C. Ramírez; M. De la Mata; P. Giner; A. Olveira; O. Nuñez; F. Jorquera; S. Duran; R. Martin-Vivaldi View Pres.


Mon, Nov 03
4:15 PM
No itinerary selected

LB5. SAMe Improves Early Viral Kinetics and Interferon Stimulated Gene Induction When Added to Peginterferon and Ribavirin Therapy for Previous Hepatitis C Non-Responders.  J. J. Feld; A. A. Modi; G. Ahlenstiel; R. El-Diwany; Y. Rotman; C. Koh; R. Titerence; Y. Park; M. Ghany; T. Heller; J. H. Hoofnagle; T. Liang View Pres.


Mon, Nov 03
4:00 PM
No itinerary selected

Session Title: Late-breaking Posters

Session Type: Poster Sessions


Location: West Hall (Moscone West Convention Center)

Start time: Mon, Nov 03 - 8:00 AM



LB7. Antiviral effects of therapeutic vaccination with naked DNA delivered by in vivo electroporation in patients with chronic hepatitis C.  M. Sällberg; H. M. Diepolder; M. C. Jung; L. Frelin; I. Mathiesen; M. P. Fons; R. W. Hultcrantz; T. Carlsson; O. Weiland View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

LB16. HCV SPRINT-1: Boceprevir plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients.  P. Kwo; E. J. Lawitz; J. McCone; E. R. Schiff; J. M. Vierling; D. Pound; M. Davis; J. S. Galati; S. C. Gordon; N. Ravendhran; L. Rossaro; F. H. Anderson; I. M. Jacobson; R. Rubin; K. Koury ; E. I. Chaudhri; J. K. Albrecht View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

LB14. High rate of HBsAg loss and HBsAg seroconversion in chronic hepatitis B patients on combination therapy with Peginterferon alfa-2a (Pegasys®) and Adefovir (Hepsera®): HBsAg titer predicts HBsAg loss or seroconversion..  B. Takkenberg; H. L. Zaaijer; C. J. Weegink; V. Terpstra; M. Dijkgraaf; P. L. Jansen; M. Beld; H. W. Reesink View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

LB9. GI5005 Immunotherapy Plus Peg-IFN/Ribavirin In Genotype 1 Chronic Hepatitis C Patients Compared To Peg-IFN/Ribavirin Alone In Naive and Non-Responder Patients; Preliminary RVR and Viral Kinetic Analysis From the GI5005-02 Phase 2 Study.  J. G. McHutchison; E. J. Lawitz; J. M. Vierling; G. T. Everson; I. M. Jacobson; M. L. Shiffman; T. D. Boyer; E. R. Schiff; S. Cruickshank; T. C. Rodell; D. Apelian View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

LB10. Antiviral Activity Of The HCV Nucleoside Polymerase Inhibitor R7128 In HCV Genotype 2 And 3 Prior Non-Responders: Interim Results Of R7128 1500mg BID With PEG-IFN And Ribavirin For 28 Days.  E. J. Gane; M. Rodriguez-Torres; D. R. Nelson; I. M. Jacobson; J. G. McHutchison; L. Jeffers; A. Beard; S. Walker; N. Shulman; W. Symonds; E. Albanis; M. M. Berrey View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

LB11. Antiviral Activity of the HCV Polymerase Inhibitor PF-00868554 Administered as Monotherapy in HCV Genotype 1 Infected Subjects.  J. L. Hammond; M. C. Rosario; F. Wagner; D. Mazur; C. Kantaridis; V. S. Purohit; K. Durham; S. Jagannatha; M. F. DeBruin View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

LB13. Results of a Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, a Non-Nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers.  M. H. Rahimy; C. A. Crowley; J. L. Freddo; M. V. Sergeeva; B. Golec View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

LB12. BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study.  R. Nettles; C. Chien; E. Chung; A. Persson; M. Gao; M. Belema; N. A. Meanwell; M. p. DeMicco; T. C. Marbury; R. Goldwater; P. Northup; J. Coumbis; W. K. Kraft; M. R. Charlton; J. C. Lopez-Talavera; D. Grasela View Pres.


Mon, Nov 03
8:00 AM
No itinerary selected

Blank
Avatar_m_tn
LB8. Safety and antiviral activity of TMC435350 in treatment-naïve genotype 1 HCV-infected patients.  M. P. Manns; H. W. Reesink; C. Moreno; T. Berg; Y. Benhamou; Y. J. Horsmans; G. M. Dusheiko; R. Flisiak; P. Meyvisch; O. Lenz; K. Simmen; R. Verloes View Pres.



59. A functional genomic screen identifies cellular cofactors of HCV replication.  A. W. Tai; L. F. Peng; R. T. Chung View Pres.


Sun, Nov 02
4:15 PM
No itinerary selected

57. Establishment and genetic analyses of cytopathogenic HCV-JFH1 mutants by plaque-forming assay..  K. Mishima; N. Sakamoto; Y. Sekine-Osajima; M. Nakagawa; Y. Itsui; M. Tasaka; Y. Nishimura-Sakurai; G. Suda; Y. Onuki; M. Yamamoto; T. Wakita; M. Watanabe View Pres.


Sun, Nov 02
3:45 PM
No itinerary selected

54. THE STRUCTURAL ANALYSIS OF HIGHLY PURIFIED INFECTIOUS HCV PARTICLES PRODUCED IN CULTURED CELLS.  K. Morikawa; D. Akazawa; M. Imawari; T. Wakita View Pres.


Sun, Nov 02
3:00 PM
No itinerary selected

58. Altered Regulation of Extrinsic and Intrinsic Apoptosis Pathways in HCV-infected HCC cells Enhances Susceptibility to Apoptosis Induced by anti-TRAIL Receptors Agonistic Antibodies.  A. C. Frank; X. Zhang; S. Kottilil; M. Daucher View Pres.


Sun, Nov 02
4:00 PM
No itinerary selected

56. Suppression of interferon induction and response pathway by hepatitis C virus NS4B protein.  M. Tasaka; N. Sakamoto; M. Nakagawa; Y. Itsui; Y. Nishimura-Sakurai; C. Chen; G. Suda; K. Mishima; M. Yamamoto; Y. Onuki; M. Watanabe View Pres.


Sun, Nov 02
3:30 PM
No itinerary selected

Session Title: Parallel IV: NASH: Clinical

Session Type: Parallel Sessions


Moderator: Naga P Chalasani
Moderator: Elizabeth E Powell

Location: Room 2002/2004 (Moscone West Convention Center)

Start time: Sun, Nov 02 - 3:00 PM



60. Effect of twice daily intravenous interferon-beta booster treatment given for two weeks in patients still HCV-RNA positive at week 24 of peginterferon α-2b plus ribavirin therapy.  N. Kuzushita; E. Mita; S. Nakazuru; C. Song; T. Ohta; H. Hasegawa; K. Morita; N. Yuki; K. Yamamoto; M. Kato View Pres.


Sun, Nov 02
3:00 PM
No itinerary selected

Session Title: Parallel X: HCV: Therapeutic Development

Session Type: Parallel Sessions


Moderator: Jordan J Feld
Moderator: Charles D Howell

Location: General Session Room (Moscone West Convention Center)

Start time: Sun, Nov 02 - 4:45 PM



113. Decreased levels of microRNA miR-122 in hepatitis C patients with poor response to interferon therapy.  M. Sarasin-Filipowicz; J. Krol; I. Markiewicz; M. H. Heim; W. Filipowicz View Pres.


Sun, Nov 02
5:00 PM
No itinerary selected

114. Pharmacological Inhibitors of a New Hepatitis C Target--RNA binding by NS4B--Discovered by Microfluidic Affinity Analysis .  S. Einav; D. Gerber; P. D. Bryson; E. Sklan; M. Elazar; S. Maerkl; H. S. Dvory; E. Machlin; W. Gu; S. Quake; J. S. Glenn View Pres.


Sun, Nov 02
5:15 PM
No itinerary selected

115. Potential Role for Nitazoxanide in Combination with STAT-C Agents For the Inhibition of HCV Replication Without the Development of Resistance.  B. Korba; M. Elazar; P. Liu; J. S. Glenn; J. Rossignol View Pres.


Sun, Nov 02
5:30 PM
No itinerary selected

112. Gene Transcription Profile Links Hepatic Fibrosis and Virologic Response to Peginterferon plus Ribavirin Treatment for HCV Genotype 1 .  C. D. Howell; C. Huang; L. Bryson; Z. Liu View Pres.


Sun, Nov 02
4:45 PM
No itinerary selected

116. Response-guided therapy with peginterferon alfa-2a (40KD) plus ribavirin in patients with chronic hepatitis C genotype 1 or 4: Prospective randomized study of extended therapy in patients without a rapid virological response.  P. Ferenci; H. Laferl; T. Scherzer; M. Gschwantler; A. Maieron; H. Brunner; R. E. Stauber; M. Bischof; B. Bauer; C. Datz; K. Löschenberger; E. Formann; H. Hofer; P. E. Steindl-Munda View Pres.


Sun, Nov 02
5:45 PM
No itinerary selected

117. Long-term Low Dose Treatment with Pegylated Interferon alpha 2b for 6 years leads to a significant Reduction in Fibrosis and Inflammatory Score in a Subgroup of Chronic Hepatitis C Nonresponder Patients with Fibrosis or Cirrhosis .  S. Kaiser; B. Lutze; C. R. Werner; H. G. Hass View Pres.


Sun, Nov 02
6:00 PM
No itinerary selected

Session Title: Parallel XI: Health Services Research

Session Type: Parallel Sessions


Moderator: Hashem B El-Serag
Moderator: Richard K Sterling

Location: Room 3022 (Moscone West Convention Center)

Start time: Sun, Nov 02 - 4:45 PM



121. Patient, Provider, and Facility Characteristics of HCV Antiviral Treatment among US Veterans with HCV-HIV Coinfection.  J. R. Kramer; F. Kanwal; T. P. Giordano; P. Richardson; L. Petersen; H. B. El-Serag View Pres.


Sun, Nov 02
5:30 PM
No itinerary selected

Session Title: Parallel XV: Pathogenesis and Clinical Trials in HBV Infection

Session Type: Parallel Sessions


Moderator: Marc G Ghany
Moderator: Mindie H Nguyen

Location: Room 2005/2007 (Moscone West Convention Center)

Start time: Sun, Nov 02 - 4:45 PM



146. Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102), Preliminary Analysis .  P. Marcellin; M. Buti; Z. Krastev; S. Gurel; R. I. Balabanska; G. Dusheiko; R. P. Myers; E. Heathcote; J. Sorbel; J. Anderson; E. Mondou; F. Rousseau View Pres.


Sun, Nov 02
5:45 PM
No itinerary selected

143. Intrahepatic Expression of Genes Affiliated with Innate and Adaptive Immune Responses Immediately after Invasion and during Experimental Acute Hepadnaviral Hepatitis .  C. S. Guy; P. M. Mulrooney-Cousins; N. D. Churchill; T. I. Michalak View Pres.


Blank
Avatar_m_tn
Sun, Nov 02
5:00 PM
No itinerary selected

145. Naturally occurring mutations in the s domain of hepatitis B virus envelope proteins regulate virion secretion.  K. Ito; M. Guarnieri; T. Garcia; J. Li; J. R. Wands; S. Tong View Pres.


Sun, Nov 02
5:30 PM
No itinerary selected

147. HBsAg SERUM LEVELS CORRELATE WITH TOTAL LIVER HBV DNA BUT NOT WITH cccDNA.  E. K. Manesis; G. V. Papatheodoridis; E. Hadziyannis; T. Nastos; P. Karayannis View Pres.


Sun, Nov 02
6:00 PM
No itinerary selected

Session Title: Parallel XVII: HCV: Early non-STAT-C Clinical Development

Session Type: Parallel Sessions


Moderator: Hugo E Vargas
Moderator: Norah Terrault

Location: Room 2002/2004 (Moscone West Convention Center)

Start time: Mon, Nov 03 - 3:00 PM



170. Interim Results from a Phase 1b Dose-Escalation Study of 4 Weeks of PEG-Interferon Lambda (PEG-rIL-29) Treatment in Subjects with Hepatitis C Virus (HCV) Genotype 1 with Prior Virologic Response and Relapse to Peginterferon Alfa and Ribavirin.  E. J. Lawitz; A. Zaman; A. J. Muir; M. L. Shiffman; B. Yoffe; T. Zhang; S. Souza; D. F. Hausman View Pres.


Mon, Nov 03
4:00 PM
No itinerary selected

169. Intracytoplasmic delivery of a recombinant IgG1 antibody by adenovirus vector inhibits replication of two different HCV strains.  P. K. Chandra; S. Hazari; M. Clementi; R. Burioni; S. Dash View Pres.


Mon, Nov 03
3:45 PM
No itinerary selected

168. A Randomized, Double-Blind, Placebo-Controlled Study of PPAR-gamma Agonist Pioglitazone Given in Combination with Peginterferon and Ribavirin in Patients with Genotype-1 Chronic Hepatitis C. .  H. S. Conjeevaram; C. F. Burant; B. McKenna; D. Harsh; H. Kang; A. K. Das; L. Everett; D. White; A. F. Lok View Pres.


Mon, Nov 03
3:30 PM
No itinerary selected

166. In vivo protection against HCV by broadly neutralizing human monoclonal antibodies .  N. M. Kneteman View Pres.


Mon, Nov 03
3:00 PM
No itinerary selected

171. Cyclophilins are essential host factors for HCV RNA replication and potent cyclophilin inhibitors are potential anti-HCV drugs. .  K. Inoue; C. Matsuda; T. Watanabe; M. Yoshiba; M. Kohara View Pres.


Mon, Nov 03
4:15 PM
No itinerary selected

167. Pioglitazone improves early virologic kinetic response to Peg IFN/RBV combination therapy in hepatitis C genotype 1 naïve pts .  H. M. Elgouhari; K. B. Cesario; R. Lopez; N. N. Zein View Pres.


Mon, Nov 03
3:15 PM
No itinerary selected

Session Title: Parallel XXIII: HCV: Infection and Pathogenesis

Session Type: Parallel Sessions


Moderator: Kyong-Mi Chang
Moderator: Steven A Weinman

Location: Room 2002/2004 (Moscone West Convention Center)

Start time: Mon, Nov 03 - 4:45 PM



204. Mouse Model for Hepatitis C Virus Replication.  H. Hefler; S. Hazari; P. K. Chandra; K. Jackson; T. G. Ooms; M. E. Burow; T. K. Mandal; S. Haque; R. F. Garry; L. A. Balart; S. S. Florman; S. Dash View Pres.


Mon, Nov 03
5:15 PM
No itinerary selected

203. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation.  T. Kato; Y. Choi; G. Elmowalid; R. K. Sapp; H. Barth; T. Wakita; K. Krawczynski; T. Liang View Pres.


Mon, Nov 03
5:00 PM
No itinerary selected

205. Hepatitis C virus (HCV) induces liver fibrosis in the absence of hepatic inflammation in transgenic mice expressing the full-length HCV open reading frame.  P. Chouteau; E. Merour; H. Lerat; J. Pawlotsky View Pres.


Mon, Nov 03
5:30 PM
No itinerary selected

207. Viral Entry and Escape from Antibody-Mediated Neutralization are Key Determinants for the Selection of Hepatitis C Virus Variants During Liver Transplantation .  S. Fafi-Kremer; I. Fofana; P. Carolla; E. Soulier; M. Bastien-Valle; C. Royer; E. Schvoerer; F. Cosset; D. Jaeck; M. Doffoel; P. Wolf; S. Françoise; T. Baumert View Pres.


Mon, Nov 03
6:00 PM
No itinerary selected

202. USP18 promotes HCV replication and blunts the antiviral effect of IFNa in a protease-independent fashion .  L. Chen; J. Sun; X. Meng; E. Heathcote; A. Edwards; I. McGilvray View Pres.


Mon, Nov 03
4:45 PM
No itinerary selected

206. Ex vivo analysis of CD4+ T helper cell responses in acute HCV infection and early treatment: Early antiviral therapy preserves virus specific CD4+ cells. .  J. Schulze zur Wiesch; V. Kasprowicz; T. Kuntzen; B. E. Nolan; S. Longworth; L. L. Reyor; B. McGovern; T. M. Allen; A. W. Lohse; L. Lewis-Ximenez; W. W. Kwok; R. T. Chung; A. Y. Kim; G. M. Lauer View Pres.


Mon, Nov 03
5:45 PM
No itinerary selected

Session Title: Parallel XXIV: HCV Therapy: Clinical

Session Type: Parallel Sessions


Moderator: Tarek Hassanein
Moderator: Reem H Ghalib

Location: General Session Room (Moscone West Convention Center)

Start time: Mon, Nov 03 - 4:45 PM



210. High Predictive Accuracy of an Unbiased Proteomic Profile to Predict Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients.  K. Patel; J. Lucas; J. W. Thompson; M. A. Moseley; D. M. Uzarski; H. L. Tillmann; R. M. Califf; J. McCarthy; J. G. McHutchison View Pres.


Mon, Nov 03
5:15 PM
No itinerary selected

213. MODULATIONS OF PEG-INTERFERON PLUS RIBAVIRIN DURATION ACCORDING TO HCV-GENOTYPE AND VIROLOGIC RESPONSE AT W4 AND W12: META-ANALYSES OF RCTs WITH INDIVIDUAL DATA.  V. Di Martino; C. Richou; T. Thévenot; J. M. Sánchez-Tapias; P. Ferenci View Pres.


Mon, Nov 03
6:00 PM
No itinerary selected

211. Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection.  E. J. Lawitz; M. S. Sulkowski; I. M. Jacobson; S. Faruqui; W. K. Kraft; B. Maliakkal; M. Al-Ibrahim; R. H. Ghalib; S. C. Gordon; P. Kwo; J. Rockstroh; M. Miller; P. Hwang; J. Gress; E. Quirk View Pres.


Mon, Nov 03
5:30 PM
No itinerary selected

212. Randomized study comparing Peginterferon-alfa2a plus Ribavirin and Peginterferon-alfa2b plus Ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study .  M. Rumi; A. Aghemo; G. Prati; R. D'Ambrosio; M. Donato; A. Russo; N. Cerami; R. Soffredini; M. Colombo View Pres.


Mon, Nov 03
5:45 PM
No itinerary selected

209. Do growth factors improve SVR in chronic HCV-genotype 1 patients treated with Peg-Interferon and Ribavirin?.  M. Kugelmas; M. A. Mah'moud View Pres.

Blank
Avatar_m_tn


208. Does Induction Pegylated Interferon Alfa-2b in Combination with Ribavirin Enhance The Sustained Response Rates in Patients with Genotype 1 and 4 Chronic Hepatitis C? Results from a Prospective, Randomized, Multi-Center, Open-Label Treatment Study..  D. E. Brady; J. W. An; E. J. Lawitz; S. Harrison View Pres.


262. Strong Racial Differences in Lipid Metabolism Genetic Associations with Hepatic Fibrosis in Chronic Hepatitis C Infected Patients.  J. McCarthy; K. Patel; J. G. McHutchison View Pres.


265. Changes in Health-Related Quality of Life are Associated with Disease Progression and Peginterferon Therapy in Patients with Advanced Hepatitis C in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial.  K. K. Snow; H. L. Bonkovsky; R. J. Fontana; J. H. Hoofnagle; H. Kim View Pres.

266. Naturally occurring STAT-C resistance mutations in treatment-naïve HCV infected patients - an international multi-center study.  T. Kuntzen; J. Timm; A. Berical; A. M. Berlin; C. Oniangue-Ndza; B. Lee; D. Heckerman; J. Carlson; H. R. Rosen; F. K. Bihl; A. Cerny; U. Spengler; Z. Liu; Y. Xing; M. A. Madey; J. F. Fleckenstein; V. M. Park; C. A. Riely; G. Lake-Bakaar; E. S. Daar; I. M. Jacobson; E. D. Gomperts; B. R. Edlin; S. M. Donfield; R. T. Chung; A. Talal; T. N. Marion; B. W. Birren; M. R. Henn; T. M. Allen View Pres.


Tue, Nov 04
12:15 PM
No itinerary selected

267. Decline in Sexual Desire, Function and Satisfaction in Men During Peginterferon and Ribavirin Therapy for Chronic Hepatitis C.  L. M. Dove; R. C. Rosen; D. Ramcharran; A. S. Wahed; S. H. Belle; R. S. Brown; J. H. Hoofnagle View Pres.


Tue, Nov 04
12:30 PM
No itinerary selected

264. Lower Risk of Hepatocellular Carcinoma and Improved Survival in patients with HCV Related Cirrhosis with Sustained Virological Response.  A. F. Cardoso; R. Moucari; N. Giuily; C. G. Figueiredo-Mendes; N. Boyer; M. Ripault; C. Castelnau; T. Asselah; M. Martinot-Peignoux; S. Maylin; C. Stern; P. Bedossa; P. Marcellin View Pres.


Tue, Nov 04
11:45 AM
No itinerary selected

263. Sustained Virological Response is Associated with Decrease in Liver Stiffness Using FibroScan in Patients with HCV Related Cirrhosis.  A. F. Cardoso; C. Stern; R. Moucari; N. Giuily; C. G. Figueiredo-Mendes; N. Boyer; M. Ripault; C. Castelnau; T. Asselah; M. Martinot-Peignoux; S. Maylin; P. Bedossa; P. Marcellin View Pres.


Tue, Nov 04
11:30 AM
No itinerary selected

Session Title: Parallel XXXIII: HCV: Therapeutic Trials

Session Type: Parallel Sessions


Moderator: Bhupinderjit S Anand
Moderator: Andrew Muir

Location: General Session Room (Moscone West Convention Center)

Start time: Tue, Nov 04 - 11:15 AM



268. Sustained Virologic Response (SVR) and Predictors of Response in African American (AA) Patients in the IDEAL (Individualized Dosing Efficacy Versus Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) Phase 3b Study.  J. McCone; K. Hu; J. G. McHutchison; M. L. Shiffman; J. W. King; S. K. Herrine; G. Galler; M. Sulkowski; F. Nunes; K. a. Brown; S. C. Gordon; K. D. Mullen; N. Ravendhran; W. M. Cassidy; R. H. Ghalib; W. Deng; S. Noviello; J. K. Albrecht; A. J. Muir View Pres.


Tue, Nov 04
11:15 AM
No itinerary selected

271. Reduction of Insulin Resistance with Effective Clearance of Hepatitis C Infection: Results from the HALT-C Trial.  A. Delgado-Borrego; S. H. Jordan; B. Negre; D. Healey; W. Lin; D. A. Ludwig; A. F. Lok; J. E. Everhart; R. T. Chung View Pres.


Tue, Nov 04
12:00 PM
No itinerary selected

273. Reduced Hepatic Inflammation is Related to HCV RNA Suppression and Correlates With Less Fibrosis Progression and Fewer Cirrhosis Complications in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.  C. Morishima; M. L. Shiffman; K. Lindsay; G. Szabo; J. L. Dienstag; E. C. Wright View Pres.


Tue, Nov 04
12:30 PM
No itinerary selected

270. Es-Citalopram for the prevention of PEG-IFN-α and Ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study)..  M. Schaefer; R. Sarkar; U. Spengler; T. Schlaepfer; J. Ockenga; A. Friebe; S. Effenberger; L. M. Heinze; P. Buggisch; J. Reimer; R. Link; A. Klein; B. Hintsche; V. Weich; F. Boemmel; S. Zeuzem; T. Berg View Pres.


Tue, Nov 04
11:45 AM
No itinerary selected

269. A Phase 2b Study of Telaprevir with Peginterferon-Alfa-2a and Ribavirin in Hepatitis C Genotype 1 Null and Partial Responders and Relapsers Following a Prior Course of Peginterferon-Alfa-2a/b and Ribavirin Therapy: PROVE3 Interim Results.  J. G. McHutchison; M. L. Shiffman; N. Terrault; M. P. Manns; A. M. Di Bisceglie; I. M. Jacobson; N. H. Afdhal; E. Heathcote; S. Zeuzem; H. W. Reesink; S. George; N. Adda; A. J. Muir View Pres.


Tue, Nov 04
11:30 AM
No itinerary selected

272. Treatment Week 24 Results of Weight-based Taribavirin Versus Weight-Based Ribavirin, Both with Peginterferon alfa-2b, in Naïve Chronic Hepatitis C, Genotype 1 Patients .  E. Lawitz; A. J. Muir; F. Poordad; E. Chun; J. Hammond View Pres.


Tue, Nov 04
12:15 PM
No itinerary selected

Session Title: Presidential Plenary II

Session Type: Plenary Sessions


Moderator: Scott L Friedman
Moderator: Jacquelyn J Maher

Location: General Session Room (Moscone West Convention Center)

Start time: Mon, Nov 03 - 11:00 AM



158. Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 103), Preliminary Analysis .  E. Heathcote; E. J. Gane; R. A. deMan; S. Chan; W. Sievert; S. Mauss; P. Marcellin; J. Sorbel; J. Anderson; E. Mondou; J. Quinn; F. Rousseau View Pres.


Mon, Nov 03
12:05 PM
No itinerary selected

157. Transcriptional activity of hepatits B virus covalently closed circular DNA(HBV cccDNA) is regulated by methylation.  J. Kim; S. Jeong View Pres.


Mon, Nov 03
11:50 AM
No itinerary selected

Session Title: Presidential Plenary III

Session Type: Plenary Sessions


Moderator: Arun J Sanyal
Moderator: T. Jake Liang

Location: General Session Room (Moscone West Convention Center)

Start time: Tue, Nov 04 - 8:00 AM



242. Peginterferon with or without Ribavirin for Chronic Hepatitis C in Children and Adolescents: Final Results of the PEDS-C Trial.  K. B. Schwarz; R. P. Gonzalez-Peralta; K. F. Murray; J. P. Molleston; B. Haber; M. M. Jonas; P. Mohan; W. F. Balistreri; P. Rosenthal; M. R. Narkewicz; L. J. Smith; P. R. Robuck; B. Barton View Pres.


Tue, Nov 04
9:15 AM
No itinerary selected

243. Telaprevir in Combination with Peginterferon-Alfa-2a with or without Ribavirin in the Treatment of Chronic Hepatitis C: Final Results of the PROVE2 Study.  S. Zeuzem; C. Hezode; P. Ferenci; G. M. Dusheiko; K. Alves; L. Bengtsson; S. Gharakhanian; R. Kauffman; J. J. Alam; J. Pawlotsky View Pres.


Tue, Nov 04
9:30 AM
No itinerary selected

Session Title: Viral Hepatitis: Co-morbidities and Non-B/Non-C Hepatitis Viruses

Session Type: Poster Sessions


Location: West Hall (Moscone West Convention Center)

Start time: Tue, Nov 04 - 8:00 AM


Blank
Avatar_m_tn
1945. Association of Lipid Profiles with Hepatitis C Viral Load in Chronic Hepatitis C Patients with Genotype 1 and 2 Infection.  C. Hsu; C. Liu; C. Liu; M. Lai; P. Chen; D. Chen; J. Kao View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1946. Low Rate of Anamnestic Response to Hepatitis B Vaccine in Patients with HIV and Isolated Hepatitis B Virus (HBV) Core Antibody.  I. G. Harnik; P. Heeger; D. A. Fishbein View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1957. Hepatitis A viremia in the course of hepatitis A by real-time PCR.  K. Fujiwara; H. Kojima; S. Yasui; Y. Yonemitsu; M. Arai; K. Fukai; F. Imazeki; O. Yokosuka View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1931. Prospective evaluation by paired liver biopsy of HCV disease progression in patients (pts) co-infected with HIV. .  R. K. Sterling; P. G. Smith; J. Wegelin; M. L. Shiffman; R. T. Stravitz; V. A. Luketic; M. Fuchs; A. J. Sanyal View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1937. Increasing CD4 Percentage During Chronic HCV Treatment In An HIV/HCV Integrated Clinical Cohort .  L. Beauchamps; J. S. Kalpoe; D. Tider; A. Stivala; D. A. Fishbein View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1935. Prevalence and Predictors of Liver Fibrosis in Hepatitis C (HCV) Infected Hemophilic Men .  M. Ragni; K. Soadwa; M. A. Nalesnik; Q. Dang View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1939. Effect of Anti-TNF-α Blockers on serum ALT levels in Potential Hepatitis B Virus Occult Carriers.  J. Sohn; T. Kim; Y. Jeon; D. Han; C. Eun; H. Choi View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1940. IP-10 correlates with HCV viral load, hepatic inflammation and fibrosis and predicts HCV response, relapse or non-response in HIV-HCV co-infection.  T. Reiberger; J. H. Aberle; M. Kundi; A. Rieger; H. Holzmann; M. Peck-Radosavljevic View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1941. Marginal zone lymphoma and HCV infection: role of antiviral treatment.  A. M. Pellicelli; G. Barbaro; V. Zoli; D. Remotti; R. Villani; L. Nosotti; A. Picardi; U. Vespasiani Gentilucci; F. Soccorsi View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1952. Hepatocellular Carcinoma associated to chronic Hepatitis Delta.  R. Romeo; A. Russo; A. Sangiovanni; E. Del Ninno; M. Rumi; M. Colombo View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1949. Insulin Resistance is Not Associated with Histologic Severity in Nondiabetic, Noncirrhotic Patients with Chronic Hepatitis B Virus Infection.  S. Park; D. Kim; Y. Kim; B. Kim View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1943. The presence of additional diagnoses in patients with chronic hepatitis B and C. Histological evaluation of liver biopsies used for correlation with Transient Elastography in 257 patients..  C. Verveer; P. E. Zondervan; H. L. Janssen; R. J. de Knegt View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1950. Epidemiology and genetic analysis of Hepatocellular Carcinoma in Morocco.  S. Benjelloun; A. Essaid El Feydi; A. Marchio; A. Akil; L. ElKihal; R. Afifi; M. Hassar; M. Benazzouz; S. Ezzikouri; P. Pineau View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1930. Whole Genome Transcriptional Profiling in Peripheral Blood Mononuclear Cells Illustrates Unique Pathogenic Characteristics of HCV Mixed Cryoglobulinemic Vasculitis .  S. Kottilil; A. C. Frank; J. Yang; R. A. Lempicki; M. G. Ghany; M. Sneller View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1936. A clinicopathological comparison of HIV/Hepatitis B co-infection and Hepatitis B mono-infection in Cape Town, South Africa.  M. W. Sonderup; H. Wainwright; H. N. Hairwadzi; C. W. Spearman View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1955. Clinical Impact of Hepatitis E Virus (HEV) on Acute Hepatitis of Unknown Etiology During 10 Years in Sapporo, Japan.  J. Kang; H. Mizuo; Y. Karino; T. Matsui; J. Koyama; S. Honjo; T. Arakawa; H. Okamoto; S. Mishiro View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1959. 11-year Change of Hepatitis A Prevalence in Single City of Korea.  J. Lee; D. Son; H. Park; H. Park; J. Park; J. Lee; S. Jung; D. Lee; H. Kim; Y. Shin; Y. Kim View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1953. HBEAG-POSITIVE DELTA HEPATITIS: VIROLOGICAL; BIOCHEMICAL AND CLINICAL FEATURES IN A LARGE EUROPEAN MULTICENTER DATA BASE .  B. Heidrich; H. Wedemeyer; M. Bektas; R. Idilman; F. Önder; A. Bozdayi; K. Zachou; K. Deterding; R. Raupach; H. Bozkaya; M. P. Manns; C. Yurdaydin View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1944. Predictors of liver related mortality and morbidity in chronic HBsAg carriers.  Y. Ngo; V. Thibault; M. Rachel; D. Rousselot-Bonnefont; V. Ratziu; T. Poynard; Y. Benhamou View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1948. What should be the definition of normal ALT serum level for identification of chronic hepatitis B inactive carrier? .  Y. Ngo; V. Thibault; M. Rachel; V. Ratziu; D. Rousselot-Bonnefont; T. Poynard; Y. Benhamou View Pres.


Blank
Avatar_m_tn
Tue, Nov 04
8:00 AM
No itinerary selected

1933. Effects of Hepatitis C Virus Core Protein on Insulin Signaling: Study of Core Protein of different Genotypes and Amino-acid Sequence Analysis .  C. Sophie; S. Pascarella; V. Pazienza; K. Guilloux; S. Conzelmann; F. Negro View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1960. Difference of Liver Stiffness after Acute or Chronic Liver Injury due to Viral Hepatitis.  J. Kim; H. . Yim; Y. Jung; J. Kim; Y. Seo; J. Yeon; S. Um; K. Byun View Pres.



1938. Effect of Rituximab on advanced liver disease in patients with HCV-related mixed cryoglobulinemia.  A. Petrarca; L. Rigacci; U. Arena; F. Vizzutti; C. Giannini; P. Montalto; A. Bosi; S. Colagrande; P. Romagnoli; G. Laffi; A. Zignego View Pres.


1932. Selective up-regulation of interferon-inducible genes and type 1 and type 2 interferons in the brain of patients with hepatitis C and severe depression .  M. Trippler; K. Truebner; T. Bajanowski; S. Bein; G. Gerken; J. F. Schlaak View Pres.



1951. Diabetes Mellitus is Associated with more Advanced Stage of Liver Fibrosis in Patients with Chronic Hepatitis C Infection. .  M. Sanon; E. Bou Assaf; S. Kirtich; G. Bahtiyar; S. I. McFarlane; A. Aytaman View Pres.


1947. HCV infection and carotid atherosclerosis: evidence in favor of a local viral action inside the plaque..  M. Boddi; B. Chellini; R. Marcucci; F. Sofi; C. Giannini; L. Gragnani; A. Piluso; D. Prisco; R. Abbate; A. Zignego View Pres.



1958. Transient Elastography (TE) as a tool to evaluate acute liver damage: a prospective, multicentric cohort study .  V. Di Marco; A. Iacò; F. Bronte; V. Calvaruso; M. Puoti; L. Biasi; K. Prestini; R. Bruno; D. Achilli; G. Squadrito; G. Amaddeo; A. Craxì View Pres.



1942. A PROSPECTIVE ANALYSIS OF FIBROTEST-FIBROSURE (FT) PROGNOSTIC VALUE AT 10 YEARS IN PATIENTS WITH CHRONIC HEPATITIS C (CHC).  Y. Ngo; M. Munteanu ; D. Messous; F. Charlotte; F. Imbert-Bismut; D. Thabut; P. Lebray; V. Thibault; Y. Benhamou; V. Ratziu; T. Poynard View Pres.


1934. Hiperbilirubinemia in patients with chronic hepatitis C may be due to UGT1A1 promoter polymorphisms. .  M. M. Souza; S. K. Ono-Nita; C. S. Ferreira; C. Zanini; H. S. Paschoale; P. D. Nasser; E. P. Carmo; M. E. Nita; F. J. Carrilho View Pres.

Blank
Avatar_m_tn
May have missed some in the copy and paste but that's what I got.

Blank
Avatar_m_tn
What in the hell is all this?
Blank
Avatar_m_tn
Sorry Rocker, it's nothing you can eat or put in a shake.
Blank
Avatar_m_tn
Thanks for the heads up about not needing to register to gain access to the abstracts.

For some reason I thought you needed to, but then again the path to those abstracts is not exactly intuitive so maybe I didn't find it the first time without registering.

As to the doc's -- just because there name is on a paper doesn't mean they will physically be there to present. I'm sure there's a list of presenters somewhere.

For anyone interested in just a couple of the abstracts, you can probably just plug the abstract number into the search page athough I don't have it in front of me now.

-- Jim
Blank
Avatar_f_tn
Thank you, Jim. It was easier for me to plant two hundred spring bulbs today than it will be to wade through our new curriculum.

Quick question about something I noticed, unrelated to the conference study papers themselves but to the current list of substances harmful to the liver, as posted on your link in one of the tabs. It had a rather odd conclusion about the Roche COBAS TaqMan and TaqMan 48 Analyzers, that  the "FDA considers that the probability of life threatening consequences is likely to occur by the malfunctioning of these devices."


"Drug Alerts
AASLD » Your Liver » Drug Alerts » Roche COBAS TaqMan and TaqMan 48 Analyzers
Roche COBAS TaqMan and TaqMan 48 Analyzers  
FDA and Roche Molecular Systems
FDA and Roche Molecular Systems notified healthcare professionals of a Class 1 recall of the Roche COBAS TaqMan and TaqMan 48 Analyzer, used for the measurement of hepatitis B and hepatitis C viruses and for other in-house diagnostic testing. The analyzers produced falsely elevated values due to the improper seating of a fiber optic cable in the analyzer instrument. FDA considers that the probability of life threatening consequences is likely to occur by the malfunctioning of these devices.



-----------------------------------------------------------------------------------------------------------

Is this old news and now insignificant due to the necessary correction?

And now to the more serious matter at hand, picking a study to read.....any hot ones recommended by those more diligent than I've been? Shall I just cut to the highlights or do my own slogging through the brush? See you in a week....:)

    




Blank
Avatar_m_tn
I have have of herbal "extracts" but this is even too much for me
Blank
422881_tn?1257607179
Thanks for the info jmjm.

I know the meeting is not even over yet....but does anyone know when, if, or where the full summary of these presentations will be made available?
Blank
Avatar_m_tn
I think this is pretty much it except for late breaking presentations which usually end up on the site near the end.

This site here usually has summaries of key articles but they don't appear up yet -- maybe in a few days:

http://www.hivandhepatitis.com/

Also some quick links here from another site:

http://preview.tinyurl.com/5eeams



Blank
Avatar_m_tn
Here's a better link to those Quick Links from the hc advocate web site:
http://tinyurl.com/5eeams
Blank
Avatar_m_tn
Awesome links to information..thanx
Blank
422881_tn?1257607179
I think I’m thinking of something else with powerpoint slides of data available like a seminar.

Thanks again for the info. A LOT of good stuff to sort through here.
Blank
Avatar_f_tn
Wow, Jim, thanks alot!  It will take me several days to pick through all these and decide which I want to read, but thanks so much for taking the time to do this!  

Susan400
Blank
619345_tn?1310345021
Found a lot of good reading and have copied several studies to discuss with my doctor
and ditto on the time you spent  Thanks
Blank
233616_tn?1312790796
holy motherload there jmjm.....I guess this explains why my doctor doesn't know all I think he should!!!   Heaven's to Mergatroid ......

no wonder someone said....whose got time to even look at all the posters....
how are providers supposed to keep up with that much stuff being offered in one week!
It's no wonder even doc who go to these don't know the half of it.

mb
Blank
238010_tn?1293989260
Very helpful, Jim, thanks for taking the time to do this for everyone.  Much appreciated!

smaug
Blank
Avatar_m_tn
Thanks a bunch. Mike
Blank
Avatar_f_tn
Again, thanks.

Based on ID # 1851, I sure wish I were more anemic, less than 10!
Blank
Avatar_m_tn
Thanks for bringing this one to my attention.  I'm going to post the study in its own thread. .
Blank
Avatar_m_tn
Looks like hivandhepatitis ******* has finally started their annual capsulated coverage of AASLD  with easy to access hot links. Hopefully it will be more complete soon.

http://www.hivandhepatitis.com/2008icr/aasld/main.html
Blank
Avatar_m_tn
******* was starred out, above, but hopefully I'm not violating any rules since the site is medical and not commercial. Like Clinical Care Options and Projects In Knowledge, that site is an excellent resource.
Blank
Avatar_m_tn
I guess the computer is not smart enough to be context sensitive (or I'm not smart enough to realize that) ! Once more, what is missing is "d o t  c o m"
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis C Community Resources
RSS Expert Activity
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Emotional Eating Control: How to St...
Aug 28 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
163305_tn?1333672171
Blank
orphanedhawk
Rural Mural, CA
Avatar_f_tn
Blank
nan535
Brooklyn, NY
1747881_tn?1358189534
Blank
hrsepwrguy
Greeley, CO
683231_tn?1408489117
Blank
flyinlynn
Auburn, WA
1815939_tn?1377995399
Blank
pooh55811
Avatar_m_tn
Blank
can-do-man
IN